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Summary
During latency, herpesvirus infection results in the establishment of a dormant state in which a highly
restricted set of viral genes are expressed. is is associated with extensive methylation of CpG motifs in
non-expressed viral genes. Together with these alterations of the viral genome, several host genes undergo
epigenetic modications during the latent infection. In some of the human and animal herpesvirus infec-
tions, these epigenetic dysregulations of cellular genes are involved in the development of cancer. is
PhD program was carried out using an animal model of virus induced lymphoma causing the Marek’s
disease (MD) in chicken. is lymphoproliferative disease is the ultimate consequence of chicken infec-
tion with virulent strains of gallid herpesvirus-2 (GaHV-2). is Alphaherpesvirinae actually shares several
properties with Gammaherpesvirinae (such as human herpesvirus-4 and -8) which are associated with the
development of tumors under specic conditions in latently infected cells. GaHV-2 was shown to modu-
late the expression of several cellular miRNAs in chicken. Altered expressions of host-encoded miRNAs
were analyzed in vitro and in vivo in several studies. Although only few of the cellular miRNA dysregu-
lations triggered by GaHV-2 were analyzed in depth, these studies suggested that altered expressions of
host miRNAs are involved in the molecular pathways of GaHV-2 oncogenicity.
erefore, we decided to focus on a host miRNA, miR-126 since several pieces of evidence suggested
it might be downregulated during GaHV-2 tumorigenesis. Originally described as a miRNA mediat-
ing proper angiogenesis and vascular integrity, miR-126 has been reported to impair cancer progression
through signaling pathways that control tumor cell proliferation, migration, invasion and survival. MiR-
126 was shown to be downregulated in several human cancers such as in oral, stomach, colon, lung, breast,
cervix, bladder and prostate carcinoma. MiR-126 is an intronic miRNA integrated in the intron 7 of a cel-
lular gene, the epidermal growth factor like domain 7 (eg-7 ). In human, the laer gene is controlled by
three promoters generating three transcripts, a long, an alternative and a short one. It was shown that
epigenetic modications have an impact on the alternative transcript expression by remodeling the alter-
native promoter.
e core issue of this PhD program is to know whether miR-126 downregulation is a key event of GaHV-2
oncogenicity. ree study were carried out in order to bring some insights.
e rst part of this work, was to set up a thorough quantication method of miR-126 expression. is
method is essential to compare, in the most accurate way, miR-126 expression level in any situation corre-
sponding to the dierent stages of GaHV-2 infection. e quantication method was tested during an in
vivo challenge with a chicken line highly sensitive to MD (B13/B13 strain). Chickens were infected with
a very virulent strain of GaHV-2 (RB-1B). e method relied on the use of several reference genes (RGs):
gapdh, β-actin, small nuclear RNA U6 (U6), 18SrRNA, Hydroxymethylbilan synthase (hmbs) and succinyl
dehydrogenase (sdha). e three RGs that showed the most stable expression were selected with an Excel-
based soware (GeNorm) and used to normalize the expression level of three cellular genes (miR-126, cd4
and cd8) and one viral one (meq, the major oncogene of GaHV-2). e results showed that depending on
the RG used, dierent conclusions have been obtained. e conclusion of this part is that combining sev-
eral RGs to normalize gene expression is crucial for drawing accurate conclusions from quantication data.
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e second part of this work determined miR-126 expression level at the key steps of GaHV-2 infection
(in vitro and in vivo) and looked out for epigenetic modications involved in the control of its expression.
e miR-126 expression level was evaluated by using the reliable quantication method set up in the rst
part of the study. e cellular miRNA was found to be repressed during the viral-induced oncogenesis
phase. In order to determine whether miR-126 low expression level was associated with specic epige-
netic signatures and with peculiar transcription proles, DNA methylation paerns and transcriptional
isoforms were established at miR-126 genomic locus. Repression was found to be associated with hyper-
methylation at a CpG island located in the miR-126 host gene (eg-7 ). Moreover, transcriptional isoforms
analysis showed the existence of alternative promoters during chicken development. is analysis also
permied revealing the existence of two main initiation sites associated each with a CpG islands.
Since miR-126 repression is likely to play a pivotal role in altering gene expression paerns during cell
transformation, we investigated the impact of miR-126 restoration. A strategy was developed to overex-
press miR-126 and control miRNAs in transformed CD4+ T cells propagated from MD lymphoma. To this
end, a conditional expression system (Tet-on inducible expression) was developed to counteract miR-126
shutdown. e preliminary functional analysis showed that miR-126 inhibition might participate to the
cancerous process induced by GaHV-2 by supporting cell proliferation.
To complete the in vitro functional analysis, the third part of this work concentrated on the creation of a
recombinant GaHV-2 that constitutively expresses the miRNA lost during lymphoma development. e
aim was to interfere with miR-126 silencing during the natural course of GaHV-2 infection. Recombinant
viruses expressing either wild-type or mutated versions of miR-126 were generated from a very virulent
GaHV-2 strain (RB-1B) cloned as an infectious Bacterial Articial Chromosome (BAC). Infectious viruses
were amplied and characterized in vitro to evaluate if the recombinant viruses replicate to similar levels
as the original strain and if this strategy is adapted to overexpress miR-126 together with viral infection.
Altogether, these results brought new insights on the expression and the regulation of a cellular miRNA
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1.1. MICRORNAS CHAPTER 1. INTRODUCTION
1.1 MicroRNAs
1.1.1 Introduction
MicroRNAs (miRNAs) are short, single stranded, noncoding RNA molecules of around 21-24 nucleotides
length. e rst miRNA (lin-4) was discovered more than 30 years ago in Caenorhabditis elegans and is
implicated in the regulation of nematode development (Kaufman and Miska, 2010). Few years later, the
interference RNA phenomenon was discovered (Fire et al., 1998; Timmons and Fire, 1998). Nowadays,
miRNAs are described as key regulators of the gene expression in a very large panel of living organisms
from four kingdoms: Animalia, Planta, Fungi and Protista. Interestingly, 35 viral species infecting Animals
are also known to encode miRNAs (hp://www.mirbase.org/; a large repository of microRNA sequence
information) to regulate either their own gene expression and/or their host gene expression. MiRNAs are
known to act at a post-transcriptional level in the cytoplasm but recent studies showed also an impact
of miRNAs in the nucleus (Catalanoo et al., 2016). In the cytoplasm, miRNAs are associated mainly to
repression of gene expression (Ambros, 2004) while in the nucleus miRNAs were shown to be associated
to repression and activation of gene expression (Catalanoo et al., 2016). In miRbase more than 38 000
miRNAs are identied. MiRNAs are implicated in many dierent cellular processes such as development
(Wang et al., 2007), cell dierentiation (Hao et al., 2017), proliferation (Wang et al., 2014; Yin et al., 2015)
and tissue function (Wang et al., 2014; Yin et al., 2015). Since miRNAs are crucial to maintain homeostasis
in the cell, it is not surprising that their dysregulation leads to disease such as cancer (Pichler and Calin,
2015). MiRNAs are also known to have their expression deregulated during viral infection leading to virus
persistence in the host and induction of virus-induced tumorigenesis (Piedade and Azevedo-pereira, 2016;
Fiorucci et al., 2015).
1.1.2 Biogenesis
Transcription
MiRNAs are localized either in inter or intragenic regions in which they are either isolated or grouped into
cluster (Olena and Paon, 2010). e miRNAs from intergenic region are in non-coding regions and pos-
sess their own promoter. Half of miRNAs from vertebrates are processed from introns of protein-coding
genes or genes encoding other classes of non-coding RNA (snoRNAs, miRNAs and lncRNAs) (Rodriguez
et al., 2004). e miRNAs from intragenic regions can be in introns, exons, untranslated regions and even
overlap splicing sites (splice-site-overlapping miRNA or SO-miRNA) in non-coding or coding genes (g-
ure 1.1) (Lagos-quintana et al., 2001; Godnic et al., 2013). ese intronic miRNAs are usually in the same
orientation than their host genes and they are likely to be under the control of the promoter driving the
primary mRNA transcript (Rodriguez et al., 2004).
Most of the time miRNAs are transcribed by the cellular RNA polymerase II (polII) giving long primary
transcript RNA (pri-miRNA) presenting one or several stem loop structure(s). is pri-miRNA possesses
a cap and a poly A tail on its 5’ and 3’ ends, respectively (gure 1.2 A) (Lee et al., 2004; Bortolin-Cavaille´
et al., 2009; Cai et al., 2004).
Some miRNAs were shown to be transcribed by the RNA polymerase III (polIII), known to be implicated
more specically in small RNAs synthesis (Pascale et al., 2018). In glioma, an oncomiR, miR-138, was
demonstrated to be overexpressed impacting cell proliferation and survival. is overexpression was
aributed to the binding of the leucine-zipper transcription factor CCAAT/enhancer binding protein β
(C/EBPβ) recruiting the polIII initiation complex (Pascale et al., 2018).
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Figure 1.1: Localization and nomination of intragenic microRNAs. in black bars are introns. Bold black
bars are untranslated regions (UTRs). Grey rectangles are the coding part of exons. e stem loop structure is the
microRNA. SO for splice-site overlapping miRNA. (adapted from (Maioli et al., 2014))
Figure 1.2: microRNAs biogenesis. e dierent steps of microRNA transcription and maturation are described
from gene transcription to targeted messenger RNA regulation by interference RNA (RNAi). RNA pol II/ III stands
for RNA polymerase II and III. DGCR8 stands for digeorge syndrome critical region 8. TRBP stands for human
immunodeciency virus transactivating response RNA-binding protein. RISC stands for RNA-induced silencing
complex. (adapted from (Winter et al., 2009).
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Processing in the nucleus
Concomitantly with transcription, the pri-miRNA is processed to give the precursor miRNA (pre-miRNA)
of about 70-90 nucleotides in length from the stem loop structure (gure 1.2 B). e cleavage is performed
by the microprocessor complex made of an endonuclease from RNAse III family and its cofactor, DROSHA
and Digeorge syndrome critical region 8 (DGCR8) respectively (Lee et al., 2003; Han et al., 2004; Gregory
et al., 2004; Denli et al., 2004). DROSHA contains two domains, RIIIDa that cleaves the 3’ strand and RIIIDb
which cleaves the 5’ strand adjacent to the hairpin. DGCR8 helps for the identication of the cleavage site
in the pri-miRNA structure.
In some cases, the processing of the pri-miRNA is independent of microprocessor complex and is done
by the splicing machinery allowing the release of the pri-miRNA from the intron. ese miRNAs are
called mirtrons (gure 1.1). is process is not common but is found throughout the animal kingdom
(Okamura et al., 2007; Ruby et al., 2007). Another miRNAs subset comes from short introns and they are
name agotrons (Hansen et al., 2016). e mature agotrons are similar to the pre-miRNAs (around 80-100
nt length) but they have a biogenesis independent from the microprocessor complex and Dicer. In these
specic cases, agotrons are processed by Argonaute proteins (Ago) that migrates into the nucleus. e
catalytic activity of Ago is then able to cleave the agotrons to produce a structure similar to the pre-miRNA
(Chelou et al., 2010).
e pre-miRNA is then transported from the nucleus to the cytoplasm by a RAN-GTPase dependent man-
ner with the Exportin 5 (gure 1.2 C) (Wang et al., 2011). e Exportin 5 is a protein from the karyopherin
family which has a role in structural RNA transport like tRNA (Lee et al., 2011). e complex exportin 5
and Ran GTP recognizes the 2 nucleotides in 3’ overhang structure of the pre-miRNA which means that
the recognition is based on structure and not on the sequence (Okada et al., 2009).
Processing in the cytoplasm
In the cytoplasm, the pre-miRNA is processed by another endonuclease and its cofactor, Dicer and human
immunodeciency virus transactivating response RNA-binding protein (TRBP) respectively (gure 1.2
D). It gives a miRNA duplex of about 21-24 nucleotides in length (Gatignol et al., 2005; Haase et al., 2005;
Chendrimada et al., 2005). Both strands in the miRNA duplex have a phosphate at the 5’ end and a 2
nucleotides overhang with a hydroxyl at the 3’ end. Dicer is a protein of about 218 Kda with a central
domain Piwi-Argonaute-Zwille (PAZ) implicated in the interaction with the pre-miRNA (Provost et al.,
2002). TRBP is a protein of around 50 Kda and it is essential to mediate the association of Dicer with the
RNA duplex and the recruitment of the argonaute protein 2 (Ago2) (Chendrimada et al., 2005). Dicer, TRBP
and Ago2 association is called the RNA induced silencing complex (RISC) loading complex (RLC) and is
the essential structure required to load dsRNA fragments. is trimeric complex provides foundation for
the assembly of an active RISC through the recruitment of additional proteins such as helicases (Robb
and Rana, 2007), nucleases (Caudy et al., 2003) and RNA binding proteins (Meister et al., 2005). All these
proteins are associated to Ago2 in the RISC complex.
As mentioned earlier, miRNAs undergo two catalytic processes from a precursor to give the mature
miRNA. e microprocessor complex and DICER cleave at precise location giving dened extremities on
the mature miRNA. Sometimes heterogeneous cleavage site happens creating isomiRNAs of the mature
miRNA (Lee et al., 2010; Marti et al., 2010). ese isomiRNAs have dierential target recognition, dierent
biological properties and isomiRNAs preference depend on cell type (Baran-gale et al., 2013; Vickers et al.,
2013).
RISC loading
Mature miRNAs are formed by selection of one strand of the miRNA duplex. If the RNA duplex has a
complementarity in the central region, one strand is selected (guide strand). e other one (star strand) is
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trimmed by Ago2 and is further degraded by the nuclease complex C3PO (gure 1.2 E) (Matranga et al.,
2005; Shin, 2008; Liu et al., 2009). is is the mechanism for RISC loading for the related siRNA pathway.
Most miRNA duplexes lack central complementarity and rely on strand unwinding due to the helicase
activity of the RISC complex (Maniataki and Mourelatos, 2005; Macrae et al., 2008). e selection of the
guide strand by RISC is based on thermodynamic stability. e strand with the less stable part at the 5’
terminus is selected (Khvorova et al., 2003). Sometimes the star strand might be chosen and plays a role
by targeting its own set of target mRNAs (Okamura et al., 2008; Muylkens et al., 2010).
1.1.3 Functions of microRNAs as post-transcriptional regulators
e mature miRNA recognizes its mRNA target mainly with its seed sequence. e seed is dened as
a stretch of 7 or 8 consecutive nucleotides localized at the 5’end of the mature miRNA. is nucleotide
stretch is involved in a perfect base pairing with the target mRNA in so called “seed match” sequence.
e mature miRNA binds predominantly on seed match sequences localized at the 3’UTR of its target
(Carthew and Sontheimer, 2009) but it may also bind on 5’UTR and coding sequence of the targeted RNA
(Lee et al., 2009; Forman and Coller, 2010). Moreover, three type of interactions between the miRNA and
its target are mediated through non-canonical seed pairing rules: the perfect hybridization, the 5’domi-
nant and the 3’ compensatory hybridizations (Chi et al., 2013; Seok et al., 2016; Brennecke et al., 2005).
1. A perfect hybridization between the mature miRNA and its mRNA target induces the cleavage
of mRNA strand by Ago2 (gure 1.3 A) (Liu et al., 2004). is phenomenon happens mostly in
plants and is rare in animals. An example in animals is the targeting of the hoxb8 mRNA by miR-
196a (Yekta et al., 2004). Hoxb8 is part of a homeobox (HOX) cluster genes that are a group of
related transcription factors genes crucial for development in animals (Yekta et al., 2004). MiR-196a
possesses a perfect complementarity (with the exception of a single G:U wobble) with its target site
located in the 3’UTR of hoxb8. is hybridization led to the cleavage of hoxb8 (Yekta et al., 2004). e
complementarity match sequence between miR-196a and the 3’UTR of hoxb8 is highly conserved
between human, mouse, rat, frog, zebrash and puersh.
2. A second category of miRNA target sites is the 5’ dominant sites in which targets base-pair well
to the 5’ end of the miRNA (gure 1.3 B) (Brennecke et al., 2005). In this category it is important to
distinguish two subgroups: “canonical” sites which the target pairs well at both the 5’ end and the
3’end and “seed” sites which the target has lile or no 3’ pairing support (Brennecke et al., 2005).
An example for the subgroup “canonical” sites was described in the Texel sheep (Clop et al., 2006).
Its muscle mass was due to a mutation observed in the 3’UTR of the myostatin gene (gdf8) creating
a target site for miR-1 and miR-206. ese two miRNAs are highly expressed in skeletal muscle. e
5’dominant canonical hybridization caused the translational inhibition of gdf8 contributing to the
muscular hypertrophy of the Texel sheep (Clop et al., 2006). An example for the subgroup “seed”
sites was studied in Drosophila melanogaster. e bearded gene (brd) was targeted and transla-
tionally repressed by two miRNAs, miR-4 and miR-79 (Lai, 2002). e repression brd gene led to
phenotypic eects on adult sensory organs, like loss of commitment of extra proneural cluster cells
to the sensory organ precursor fate. e brd 3’UTR contains 3 sequence elements, known as Brd
boxes, complementary to the 5’ region of the two miRNAs. e 3 box target sites consist of 7 mer
seeds with lile or no base-pairing to the 3’end of either miR-4 or miR-79 (Brennecke et al., 2005).
3. e last category is the 3’ compensatory sites which have weak 5’ base pairing and depend on
strong compensatory pairing to the 3’ end of the miRNA (gure 1.3 C) (Brennecke et al., 2005). is
group includes seed matches of 4 to 6 base-pairs and seeds of 7 or 8 bases that contain G:U pairs,
single nucleotide bulges or mismatches. An example in Human cytomegalovirus (HCMV) is the
targeting of the major histocompatibility complex I-related chain B (micb) gene by the viral miRNA,
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HCMV-miR-UL112. Micb is critical for the natural killer (NK) activation to kill virus-infected cells
and tumor cells. e repression of micb by HCMV-miR-UL112 was shown to occur during viral
infection, leading to reduced killing by NK cells (Stern-ginossar et al., 2007).
Besides the alternative binding strategies, miRNAs usually bind on their targets with an incomplete com-
plementarity leading to translation inhibition or destabilization of the mRNA leading to degradation (g-
ure 1.2 F). In this case, the degradation is not performed directly by Ago2. e targeted mRNA is recruited
to a complex containing GW182 proteins in P bodies present in the cytoplasm where translation inhibition
and degradation occur (Hammond, 2015).
For translation inhibition dierent mechanisms have been described. In normal condition, translation be-
gins with the binding of the cap with the polyA tail by the intermediate of eukaryotic translation initiation
factor E (eIF4E) and eIF4G to form a loop. Under this circular form, translation can be initiated (gure 1.4
A). A rst mechanism of translation inhibition, is to prevent the circular form of the targeted mRNA either
by deadenylation and decapping leading to degradation of the mRNA (gure 1.4 B). Deadenylation and
decaping are facilitated by CCR4-NOT and DCP1:DCP2 complexes promoting mRNA degradation by ac-
celerating its destabilization (Behm-ansmant et al., 2006). e recruitment of these complexes is possible
in the P bodies with the GW182 protein. is protein binds on the mRNA target by interaction with Ago1
in the RISC complex and induces mRNA degradation by decapping and deadenylation. Additionally, due
to deadenylation the poly A binding protein (PABP1) cannot bind on mRNA 3’ extremity preventing the
circularization of the mRNA (Carthew and Sontheimer, 2009). A second mechanism is that miRISC is able
to interfere with ribosomes. e mature miRNA was shown to block the association between the 60S ribo-
somal subunit with the preinitiation complex 40S (gure 1.4 C) (Chendrimada et al., 2007). e repression
then occurs with the impossibility for the competent ribosome to assemble at the start codon. Another
potential mechanism is the degradation of the nascent polypeptide chain cotranslationally (gure 1.4 D)
(Eulalio et al., 2008). e protease implicated in this process is not known. e third mechanism is that
miRISC enters into competition with eIF4E, EIF4G for the binding on the 5’ cap structure (gure 1.4 E). In
the RISC complex, Ago2 possesses a domain (Mid) which bears signicant similarity to eIF4E binding site
(Kiriakidou et al., 2007).
1.1.4 Transcriptional gene silencing (TGS) and transcriptional gene activation
(TGA)
As mentioned earlier, the mature miRNA is able to translocate into the nucleus with the help of dierent
transporters such as Importin 8 (IPO8) and exportin 1 (CRM1) (Weinmann et al., 2009; Wei et al., 2014;
Castanoo et al., 2009). In P bodies, miRNA and Ago protein bind to a protein containing a nuclear
localization signal (NLS) named TNRC6A allowing them to translocate into the nucleus (Nishi et al., 2013).
Among all mature miRNAs produced in the whole cell, 25 % are exclusively present in the cytoplasm.
e remaining 75 % are localized both in the nucleus and in the cytoplasm (Gagnon et al., 2014). In the
nucleus, the minimum miRISC complex is smaller and has a dierent composition than in the cytoplasm.
Moreover, miRISC may be associated with functionally dierent proteins in the nucleus and it is assumed
that it would allow RISC to harbor dierent functions. Several roles have been identied for miRNAs
located in the nucleus:
1. ere were shown to be implicated in the post-transcriptional regulation of small RNA molecules
(Tang et al., 2012; Zisoulis et al., 2012). A rst example is the repression of miR-15a/16-1 maturation
in mouse cells by miR-709 (Tang et al., 2012). A 19-nucleotide element on the primiRNA-15a/16-1
was targeted by miR-709 blocking the processing of this primRNA on a premiRNA leading to the
biogenesis suppression of miR-15a/16-1 (Tang et al., 2012). e inhibition of miR-15a/16-1 protects
from apoptosis since miR-15a/16-1 targets an anti-apoptotic gene, bcl2 (Cimmino et al., 2005).
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Figure 1.3: MiRNA hybridization groups. A. Perfect hybridization model between the entire miRNA sequence
and a part of the target mRNA 3’UTR. B. 5’dominant sites in which targets base-pair well to the 5’ end of the miRNA.
is group is divided into two subgroups: “canonical” (in which target pairs well at both 5’end and the 3’ end) and
“seed” (in which the target has lile or no 3’ pairing support). C. 3’ compensatory sites which have weak 5’ base
pairing and depend on strong compensatory pairing to the 3’ end of the miRNA. In each groups, the upper diagram
illustrates the mode of pairing between the target site (upper line) and miRNA (lower line, red) (Brennecke et al.,
2005).
Figure 1.4: Mechanisms of translation inhibition mediated by microRNAs. A. Translation of a mRNA in
normal condition. B. Circularization and degradation of the mRNA aer deadenylation and decapping process. e
deadenylation prevents the binding of the PABP1 complex. C. Inhibition of translation by preventing the association
of the two subunits of ribosomes or degradation of the nascent peptide. D. miRISC enters in competition with eIF4E
by binding the cap of the mRNA. E. degradation of the nascent polypeptide chain cotranslationally. eIF4E and G for
eukaryotic translation initiation factor4 E and G. PABP1 for ployA binding protein1. 40S and 60S for the small and
big ribosomal subunit respectively. DCP1 and 2 for decapping enzymes. CCR4 for C-C chemokine receptor type 4.
CCR4-NOT for deadenylase complex.
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2. Another potential function of nuclear miRNA would be the regulation of ribosomal RNA (rRNA)
abundance in the nucleolus (Politz et al., 2006). Several studies showed that some miRNAs are
concentrated into the nucleolus as both pre-miRNA and mature miRNA forms (Bai et al., 2014).
An example is the co-localization of miR-206 observed the 28S ribosomal RNA, in the nucleolus
and in some extend in the cytoplasm (Bai et al., 2014). e impact of this co-localization is not
fully understood but it is though that miR-206 might have an implication in 28S ribosomal RNA
abundance. Moreover, nucleoli could be a storage place allowing the release of miRNAs (precursor
and mature) rapidly in the nucleoplasm and/or cytoplasm due to a stress (Li et al., 2013).
3. An additional function of nuclear miRNAs is their implication in splicing events. Liu and collabora-
tors assumed that miRISC may bind on the nascent transcript impairing the binding of the spliceo-
some complex to the splice site without aecting pre-mRNA transcription level and stability (Liu
et al., 2012, 2015a). An example is the deletion of the exon 51 of the dystrophin transcript due to the
binding of a synthetic single stranded-siRNA on it. e action of miRISC is only possible by recog-
nition with its seed sequence on the exon sequence leading to the deletion of the targeted exon (Liu
et al., 2012, 2015a). Two other studies are in agreement to say that small non-coding RNAs (such as
miRNA) are implicated in the splicing event (Ameyar-Zazoua et al., 2012; Allo´ et al., 2009). Allo´ et
al. showed that small duplex RNA targets both intronic and exonic regions near alternative exon.
is miRNA loading favored the inclusion of a variant exon (Allo´ et al., 2009). Immunoprecipitation
assay for nuclear AGO1 and AGO2 proteins showed their interaction with core components of the
splicing machinery and several splicing factors (Ameyar-Zazoua et al., 2012). Ameyas-Zazoua et al.
showed that AGO1 and AGO2 are required for an ecient splicing event to occur (Ameyar-Zazoua
et al., 2012).
4. A last and the most studied role of miRNAs in the nucleus is the transcriptional regulation of gene
expression. Transcriptional gene activation (TGA) and transcriptional gene silencing (TGS) were
observed to be performed by the intermediate of miRNAs. e rst miRNA discovered to induce an
activation of gene expression is miR-373 (Place et al., 2008). e miR-373 nuclear import is required
to induce the expression of the E-cadherin (cdh1) and the cold-shock domain-containing protein
2 (csdc2) by binding on their promoter. Another example is the activation of lin-4 expression by
itself (Turner et al., 2014). It was observed that complementary element recognized by lin-4 was
present on its own promoter allowing transcriptional activation by triggering the recruitment of
RNA polII. Many more examples exist (Majid et al., 2010; Liu et al., 2013). e miRNA binds on
targeted promoter with its seed sequence and enhance transcription by recruitment of Ago2 pro-
tein (Huang et al., 2012) and an enrichment of RNA polymerase II (Huang et al., 2012; Matsui et al.,
2013) as well as permissive chromatin marks such as histone 3 Lysine 4 trimethylation (H3K4me3)
associated with gene expression (Huang et al., 2012). Two models exist to explain the mechanism of
how miRNA induce gene expression in the nucleus. (A) In human genome, bidirectional transcrip-
tion generates a sense orientated coding transcript and antisense orientated non-coding transcript
(mainly long non-coding RNA (lncRNA)). e laer overlaps the sense promoter. Seventy percent
of gene promoters are overlapped by non-coding RNA transcript (Gingeras, 2007). is transcript
binds on the sense promoter and induces repression of gene expression through recruitment of re-
pressive complexes (chromatin eectors and modiers). One possibility for TGA to happen is that
miRNA may have a complementary sequence with its seed sequence on the non-coding RNA. is
hybridization induces the cleavage of the laer preventing recruitment of inhibitory chromatin ef-
fectors (gure 1.5 A). It results in de-repression of the promoter activity for the sense transcript
(Morris et al., 2008; Modarresi et al., 2014). (B) e second model is that the miRNA seed sequence
still recognizes the long non coding RNA and recruits protein complexes implicated in active chro-
matin changes (gure 1.5 B). ere is then a shi of the chromatin state to have a permissive state
at the sense promoter allowing gene transcription (Matsui et al., 2013).
As mentioned previously, miRNA are also able to induce transcription gene silencing (TGS). An Example
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Figure 1.5: Potential mechanisms of miRNA guided transcriptional gene activation. Antisense orientated
long non coding RNAs (lncRNAs, orange line) is able to bind on sense promoter. e binding of the lncRNA induces
repression of gene expression through recruitment of repressive complexes (chromatin eectors and modiers). A:
miRNA may have a complementary sequence with its seed sequence on the lncRNAs. is hybridization induces
the cleavage of the laer preventing recruitment of inhibitory eectors. It results in de-repression of the promoter
activity for the sense transcript. B: miRNA seed sequence still recognizes the lncRNA and recruits protein complexes
implicated in active chromatin changes. ere is then a shi of the chromatin state to have a permissive state at
the sense promoter allowing gene transcription. TNRC6A for trinucleotide repeat-containing 6A. TRBP for human
immunodeciency virus transactivating response RNA-binding protein. AGO for argonaute. TF for transcription
factor. (Catalanoo et al., 2016)
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is the miR-223 repressing nfI-A (Zardo et al., 2012). NFI-A is a transcription factor from the nuclear factor
I family protein and is implicated in the fate of myeloid precursors. e overexpression of nfI-A drives
erythropoiesis whereas repression of nfI-A drives granulopoiesis (Zardo et al., 2012). In cells undergo-
ing granulopoiesis, miR-223 is overexpressed and it binds on nfI-A promoter. is hybridization triggers
the recruitment of polycomb (PcG) repressor complex 1 proteins member such as YY1 protein. is pro-
tein induces chromatin compaction by addition of negative chromatin marks such as histone 3 lysine 27
trimethylation mark (H3K27me3). Two mechanisms are possible to induce TGS. e rst mechanism is
that the antisense non-coding transcript serves as docking platform and miRNA bind directly on it with
its seed sequence. It allows the recruitment of RISC elements (Ago, Dicer), PcG elements (YY1, EZH2
and SUZ12) and chromatin modiers (gure 1.6 A) (Catalanoo et al., 2016). Another mechanism is the
formation of a triplex RNA*DNA:DNA (gure 1.6 B) (Toscano-garibay and Aquino-jarquin, 2014). MiRNA
would be able to bind directly on the target promoter and recruit protein complexes involved in nega-
tive chromatin remodeling. A study worked on the repression of the major promoter of dihydrofolate
reductase gene DHFR by non-coding RNA (Martianov et al., 2007). e laer induced promoter specic
transcriptional repression through disruption of the pre-initiation complex.
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Figure 1.6: Potential mechanisms of miRNA guided transcriptional gene silencing. A: the antisense non-
coding transcript serves as docking platform and miRNA bind directly on it with its seed sequence. It allow recruit-
ment of polycomb (PcG) elements (EZH2) and chromatin modier (histone deacetylase (HDAC)). B: Formation of a
triplex RNA*DNA:DNA. MiRNA would be able to bind directly on the target promoter and recruit protein complexes
involved in negative chromatin remodeling. DNMTs for DNA methyltransferases. HDAC for histone deacetylase.
AGO for argonaute. EZH2 for enhancer of zeste homolog 2. TF for transcription factor. RNApolII, RNA polymerase
II. (Catalanoo et al., 2016)
1.2 Epigenetic
1.2.1 General context
Epigenetic is the study of heritable DNA structure modication without alteration of sequence. is im-
plies a regulation of gene expression during development and in embryonic cells (Mason et al., 2012).
ese modications on genome are involved in normal development as well as in disease like cancer or
neurological disorder (Timp and Feinberg, 2013). Epigenetic is implicated in several mechanisms during
the development of an individual. It plays a role on cell dierentiation, X-chromosome inactivation and
genomic imprinting. ese modications include histone post-translational modications (HPTMs), DNA
methylation and the Long Non coding RNA recently described as triggers of the processes (Timp and Fein-
berg, 2013; Harries, 2012).
roughout life these modications may not persist. ere are precise modications at specic stages, in
several species. Some studies describe the possible impact of the environment on DNA methylation and
histone modications alteration (Feil and Fraga, 2012).
For example in insects, they undergo important morphological modications due to stress from environ-
ment. In the presence of predators or when the population density is too high, aphids can pass from
wingless to winged individual (gure 1.7 A). is change occurs during the early stage of development.
is arthropod, as Daphnia, possesses orthologues of vertebrate DNMTs but it is unknown if there is al-
teration of DNA methylation during this phenomenon (Feil and Fraga, 2012).
In plants there are also epigenetics changes. For example, Linaria vulgaris (yellow toadax) presents a
phenotypical plasticity. Indeed, their symmetry can be heritably radial or bilateral (gure 1.7 B), these
11
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Figure 1.7: Links between epigenetic modications and environmental factor. A: Female genetic polymor-
phism, two morphological morphs: wingless and winged individual. B. Face view of a Linaria vulgaris with bilateral
(up) and radial (down) symmetry. C: Mother diet (bisphenol A, BPA) inuences coat color (up) and reduced DNA
methylation on Avy gene (down) of ospring born. (Braendle et al., 2006; Cubas et al., 1999; Dolinoy et al., 2007)
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two symmetries are possible thanks to DNA methylation alteration at a gene (cycloidea gene) encoding a
transcription factor that controls dorsal asymmetry (Cubas et al., 1999).
e diet and contact with toxic component can also lead to phenotypic eects in animals. Small mod-
ications of DNA methylation were observed. Several studies are trying to determine whether these
small modications have an impact on developmental and metabolic events at the early life stage (Hei-
jmans et al., 2008; Tobi et al., 2009). e epigenetic alteration mainly occurs during the early stage of
development because this is during this phase that epigenetic paern takes place. en, the alteration
phenomenon is amplied due to cell division and thus it aects a large cell number. In mammals dierent
diet components (folate, vit B6, vit B12, methionine, choline,. . . ) have been found to alter DNA methyla-
tion and histone epigenetic marks. e CpG methylation level of the agouti viable yellow (Avy) promoter,
in mouse, showed a decrease in the next ospring when mother diet is supplemented with bisphenol A
(BPA, a compound used in plastic) (gure 1.7 C). In the next generation it was observed a large number
of yellow coat mice with diabetes and obesity problem (Dolinoy et al., 2007). ese results show that
epigenetic modications during early developmental stages can have a deep impact on health.
1.2.2 Histone post-translational modications (HPTMs)
Several HPTMs exist on the histone N-terminal tail and they aect the chromatin structure. ereby,
modications inuence gene transcription and other mechanisms as repair, replication and recombination
(Bannister and Kouzarides, 2011). e best described modications are histone acetylation, phosphoryla-
tion and methylation (Moore et al., 2013). Histone phosphorylation will not be described.
ere are over one hundred of HPTMs described in literature. Depending on what we observed, one his-
tone modication or a combination of these modications, the eect on promoter activity is not the same.
For example, the trimethylation of histone 3 lysine 4 (H3K4me3) and the acetylation of the histone 4 lysine
16 (H4K16Ac), separately, generate a permissive stage of the chromatin. But when these two modications
are present in combination that generates a restrictive stage of the chromatin (Rando, 2012). e combi-
nation of dierent histone modications is called histone code. is mechanism is not fully understood
and some scientists don’t agree with this hypothesis.
Histone acetylation
Histone acetylation consists on the transfer of an acetyl group from acetyl-CoA to a lysine residue (g-
ure 1.8). Two types of enzymes having opposite functions regulate this reaction: histone acetyl-transferase
(HAT) and histone deacetylase (HDAC).
HAT give the acetyl group on the histone 4 at lysine 5 (H4K5) and lysine 12 (H4K12) and certain ly-
sine residues on histone 3 (H3) (Table 1.1) (Bannister and Kouzarides, 2011). is reaction allows the
development of the permissive state of chromatin called euchromatin. is state promotes the gene tran-
scription by enhancing the DNA accessibility to transcription factors. Conversely, HDAC deacetylates
lysine residues. HDAC is actually composed of a variety of enzymes and is functional by association with
Figure 1.8: Histone acetylation with histone acetyl transferase (HAT) and histone deacetylase with deacetylation
with histone deacetylase (HDAC). TF stands for transcription factor. Ac stands for acetyl group.
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other HDAC family members. For instance, HDAC 1 is found together with HDAC 2 within a complex
called Nucleosome remodeling and deacetylase (NuRD) (gure 1.9) (Yang and Seto, 2008). ere are four
classes of HDAC. ey are sorted according to their sequence similarity and their function. Class I HDACs
(HDAC 1, 2, 3 and 8) are located in the nucleus and possess the highest activity. ey are ubiquitous and
play crucial roles in normal cells (Adhya and Basu, 2010). Class II HDACs (HDAC 4, 5, 6, 7, 9 and 10) can
shule from the nucleus to the cytoplasm and vice versa. is class possesses a tissue specic expression
and has a lower deactylase activity than class I (Ruijter et al., 2003). ese two rst classes are Zn2+ -
dependent classical HDAC and they are inhibited by trichostatin A (TSA). e third class is the sirtuins
(class III HDAC). e class III members are considered as NAD+ dependent and insensitive to TSA (Adhya
and Basu, 2010). e fourth class is atypical but possesses similarity in sequence with the other classes
(HDAC 11) (Adhya and Basu, 2010).
Histone methylation
Methylation of specic lysine residues located on histones is a mechanism commonly used in plants,
animals and fungi. is mechanism aims both at defensing genome integrity and at regulating gene ex-
pression (Smith et al., 2010).
Histone methylation occurs on lysine and arginine on the side chain of histones. is modication is more
complex than acetylation. Indeed, lysine can be mono-, di- or tri-methylated and arginine can be mono-,
symmetrically or asymmetrically dimethylated (gure 1.10) (Bannister and Kouzarides, 2011). e methyl
group is provided by the S-Adenosyl methionine (SAM). Specic lysines are methylated by histone lysine
methyltransferase (HKMT) at precise degrees. For instance in human, DIM5 (histone methyltransferase)
tri-methylates H3K9 causing the restrictive stage of chromatin called heterochromatin whereas SET7/9
(SET-domain protein methyltransferase superfamily) only mono-methylates H3K4 causing the activated
stage of chromatin, euchromatin (Table 1.1) (Xiao et al., 2003). For arginine, it exists two types of argi-
nine methyltransferase, type-I and type-II. ese two types are family members of the protein arginine
N-methyltransferase 1 (PRMT). e most known members are PRMT 1, 4, 5 and 6 (Bedford and Clarke,
2009).
Histone demethylases are less known enzymes; the rst lysine demethylase was identied in 2004 and
is called lysine specic demethylase 1 (LSD-1). When LSD-1 is associated with the Co-REST repressor
complex, it demethylates histone H3K4 while when it is associated with androgen receptor, it demethy-
lates H3K9 (Bannister and Kouzarides, 2011). is allows LSD-1 having either an activator or a repressor
function. Following the discovering of LSD-1, other classes of lysine demethylases were described like
JMJD2. e laer is able to demethylate a tri-methylated lysine as H3K9me3 (Whetstine et al., 2006).
It should be noticed that there are less known histone modications such as ADP ribosylation, ubiquiti-
Table 1.1: eect of histone modications on chromatin
Modication type Histone
H3K4 H3K9 H3K14 H3K27 H4K5 H4K12
Mono-me + + + + +
Di-me + - -
Tri-me + - -
Acetylation + + +
Table notes: . + represents positive mark of histone modication (open chromatin (euchromatin)). –
represents negative mark of histone modication (close chromatin (heterochromatin)). H3K4 stands for
the lysine 4 of the histone 3. me stands for methyl group.
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Figure 1.9: e NuRD complex is composed of the histone deacetylase HDAC1 and HDAC2, the histone-binding
proteins RbAp46 and RbAp48, the nucleosome remodeling enzyme Mi-2, the metastasis-associated proteins MTA1
and MTA2 and the methyl binding domain MBD3. e NuRD complex interacts with sequence-specic DNA-binding
proteins (repressors, e.g. MeCp2, an ubiquitin-like with PHD and Zn2+ domain (UHRF) proteins) and/or is recruited
by MBD2 to methylated DNA resulting in transcriptional repression. (Crook et al., 2006)
Figure 1.10: e protein methyltransferase family. A: Protein arginine methyltransferase family (PRMT). In
this picture is represents the class I and II. ese two classes are able to mono-methylated arginine. e type I
enzyme catalyzes the asymmetric dimethylarginine generation and the type II enzyme generates the symmetric
methylarginine. (B) Protein lysine methyltrasferase family (histone methyl transferase (HMT)). e dierent type
of methylation paern on histone lysine. It is unknown if this is the same enzyme that make all the dierent methyl-
lysines. (Bedford and Richard, 2005; Zhang and Reinberg, 2001)
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nation and symoylation but these will not be detailed in this paper.
1.2.3 DNA methylation
DNA methylation was discovered long time ago in the 1940’s. Several studies, until 1980’s, have shown
that DNA methylation could play a crucial role in the gene expression and cell dierentiation (Moore
et al., 2013). Actors involved in the DNA methylation are DNA methyltransferases (DNMTs). eir source
of methyl group is already introduced (SAM). ere are two types of DNMTs. e rst category adds a
methyl group on a previously unmodied DNA (DNMT3a and DNMT3b, De novo DNMTs). e second
type is active during DNA replication and allows the preservation of DNA methylation paern on the
newly synthetized DNA strand (DNMT1, perpetuating DNMT) (gure 1.11) (Moore et al., 2013).
Dierent roles of DNA methylation are identied such as regulation of gene expression according to the
cell type, X chromosome inactivation and the genomic imprinting (Moore et al., 2013). DNMT3a and
3b possess a conserved DNA binding domain PWWP (proline-tryptophan-tryptophan-proline) (Ge et al.,
2004). It is however unclear how DNMT3a and 3b recognize their specic binding site. ere are two
theories to explain the recognition of a specic DNA sequence. e rst one is that RNA interference
could help DNMT to reach the appropriate DNA sequence. e second one is that transcription factors
could recruit DNMT to specic site (Moore et al., 2013). DNA methylation is recognized by dierent kinds
of protein family: methyl-CpG binding domain (MBD) proteins and ubiquitin-like with PHD and zing
nger domain (UHRF) proteins (Nan et al., 1993). e best known member of the MBD family is MeCP2
(Methyl CpG binding protein 2); it induces a chromatin restrictive stage. Indeed, it recruits chromatin re-
pressors like histone deacetylase present in the nucleosome remodeling and deacetylase complex (NuRD)
(gure 1.9) and histone methyltransferase (Chavez et al., 2010). In addition, MeCP2 can recruit DNMT1 to
hemimethylated DNA during replication (Kimura and Shiota, 2003).
DNA methylation mainly occurs in CpG Islands, which designate DNA regions rich in dinucleotide cy-
tosin/guanine (CpG), showing a CG content higher than 40 percent and spreading over a minimum of
200 base pairs. CpG Islands are primarily located in promoter region. Transcriptionally active promoters
are associated with unmethylated CpG islands. Moreover DNA methylation might be associated with
transcriptional repression or activation. is is due to the fact that transcription factors (activators or
silencers) are either impaired or favored to bind their DNA response element when they are methylated
(Chavez et al., 2010). A recent study showed that DNA methylation not only occurs on promoter and in
Figure 1.11: e DNA methyl-transferase (DNMT) family. A: DNMT3A and 3b add a methyl group on an
unmodied DNA. B: DNMT1 acts during DNA replication and allows the preservation on DNA methylation paern
on the newly synthetized DNA strand (Moore et al., 2013).
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classical CpG islands (Irizarry et al., 2009). is study showed the existence of a sequence that mapped
up to hundreds Kb far from the transcriptional start site (TSS) called “CpG island shores” (Irizarry et al.,
2009). ese regions are actively involved in the regulation of gene expression.
1.3 Splicing mechanism
In eukaryotic cells, most of the primary messenger RNA transcripts (pre-mRNA) transcribed by RNA
polymerase II undergo post-transcriptional modications allowing their maturation and their regulation.
One of these modications is the splicing of the pre-mRNA to a mature mRNA which will be translated
into a protein in the cytoplasm. is phenomenon happens on more than 90 % of eukaryotic genes and is
carried out by the spliceosome. It is a ribonucleoprotein complex characterized by the presence of small
nuclear RNAs U1, U2, U4/U6 and U5 organized in small nuclear ribonucleoprotein particles (snRNPs)
(Baralle and Baralle, 2017). In a subset of eukaryotes, there is also a minor spliceosome, involved in the
splicing of 1 % of human genes, formed by U11/U12 and U4atac/U6atac snRNPs, that are functionally
comparable to the components of the major one (Turunen et al., 2013).
1.3.1 Splicing consensus sequences
Spliceosome complex assembly is directed by the consensus sequences that mark the exon/intron bound-
aries. e exon/intron junction at the 5’ of the intron is called the donor site (5’ splice site), the intron/exon
junction at the 3’ of the intron is called the acceptor site (3’ splice site) and the internal sequence of the
intron is called the branch point (gure 1.12). e branch point contains an adenine important for the rst
trans-esterication step of the splicing reaction and is localized in a pyrimidine rich region.
As mentioned previously, it exists two types of spliceosomes in eukaryotes. e major spliceosome is an
U2-dependent spliceosome and the minor one is an U12-dependent spliceosome. In contrast to U2-type
spliceosome found in all eukaryotes, the U12-type spliceosome is only present in vertebrates, some fungi,
nematodes and plants (Turunen et al., 2013).
e U2-type intron is conserved with a donor site corresponding to a AG/GU sequence, an acceptor site
corresponding to a YAG/R (Y=C/U;R=A/G) and an adenine at the branch point located in a CURACU
sequence called the polypyrimidine tract (PPT) (gure 1.12A). e U12-type intron is characterized by a
/RUAUCCUUU sequence at the donor site and a UUCCUURAY sequence at the branch site (gure 1.12B)
(Turunen et al., 2013). As the U2-type intron, the most used termini by the U12-type spliceosome are
/GU-AG/. Nevertheless, one third of the termini found was /AU-AC/ (gure 1.12B) (Dietrich et al., 2005).
e U12-type introns were suggested to have a role in regulating the expression of specic sets of genes
since they were found in genes related to information processing function such as DNA replication and
repair, transcription, RNA processing and translation (Turunen et al., 2013). ey were also found to be
present at genes related to cytoskeletal organization, vesicular transport, and voltage-gated ion channel
activity (Turunen et al., 2013).
1.3.2 Spliceosome assembly
e two spliceosomes coexist in the eukaryotic cells and although their snRNPs composition is dierent,
the splicing mechanism is very similar (Turunen et al., 2008).
e spliceosome catalytic conformation or complex C is formed in several successive steps with the for-
mation of intermediate complexes names complex E, A and B (Turunen et al., 2013). It is important to note
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Figure 1.12: Comparison of the U2- and U12-type regulatory consensus sequences.A: U2-type intron repre-
sentation. B: U12-type intron representation. e adenine from the branch point is wrien in red. Bold nucleotides
represent conserved nucleotides.
that no complex E is formed during a U12-type splicing event (gure 1.13). e splicing carried out by
U2-type spliceosome begins with the binding of the snRNP U1 at the donor site, splicing factor 1 (SF1) at
the branch point and the U2 snRNP auxiliary factor (U2AF) dimer at region rich in pyrimidine (U2AF65)
and the acceptor site (U2AF35) to form the complex E (gure 1.13A). At the second step, the SF1 factor is
replaced by the snRNP U2 at the adenine from the branch point. is leads to the formation of the complex
A then B by addition of the tri-snRNP U4/U5/U6 (gure 1.13B and C). ereaer, the catalytic complex
is formed with the release of U4 and U1 allowing the interaction of the three snRNP U2/U5/U6. U6 and
U2 interaction leads to the rapprochement of the acceptor site and the branch point. is rapprochement
between these two structures allows the rst trans-esterication reaction (complex C) (gure 1.13D). e
second trans-esterication reaction is carried out by U5 and leads to the exons ligation and introns exci-
sion. Finally, the spliceosome breaks up to release the snRNPs. ey will be re-used for another splicing
event.
Apart from the rst step, U12-type spliceosome assembly is similar to the U2-type spliceosome. U12 and
U11 form a stable complex binding at the acceptor site and the branch point leading to the formation of
the complex A (Turunen et al., 2008). en the snRNPs from the U12-type spliceosome interact with the
pre-mRNA as the snRNPs of the U2-type spliceosome (gure 1.13) (Schneider et al., 2002).
1.3.3 Alternative splicing
More than 95 % of genes undergo alternative splicing (Keren et al., 2010). is phenomenon is implicated in
the regulation of tissue-specic gene expression regulation by generating dierent protein isoforms play-
ing roles in various cellular processes (Maniatis and Tasic, 2002). Around 50 % of the alternative splicing
events produce variable quantities of the relevant isoforms in dierent tissues leading to a tissue-specic
isoform expression (Wang et al., 2008a). ese are responsible for development and tissue identity (Bar-
alle and Baralle, 2017). It exists several types of alternative splicing paerns through which exons can be
included or skipped (cassee exon), extended or shortened by using alternative 5’ donor or 3’ acceptor
sites as well as alternative promoters or polyA signal, and introns can be removed or retained (gure 1.14)
(Baralle and Baralle, 2017).
In order to dene exons from introns and to regulate splicing event, auxiliary sequences are essential for
both constitutive and alternative splicing. ese sequences are classied according to their eect and posi-
tion as exonic splicing enhancers and silencers (ESE and ESS, respectively) and intronic splicing enhancers
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Figure 1.13: Comparison of the dierent steps ofU2- andU12-type spliceosome assembly. U1, U2, U4/U6, U5,
U11/U12, U4atac and U6atac represent small nuclear RNAs organized in small nuclear ribonucleoprotein particles
(snRNPs). SF1 stands for splicing factor 1. U2AF stands for U2 snRNP auxiliary factor, it represents a dimer comprised
of U2AF65 and U2AF35 (U2AF65/35)
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Figure 1.14: Schematic representation of possible pre-mRNA splicing outcomes. 1. Cassee exon: inclusion
or exclusion can occur at varying proportions. Exon inclusion/exclusion can be altered by changes in transcription
initiating site through the use of dierent promoters, forming alternative 5’-terminal exons joining to a common 3’
exon. is mechanism can also dene the use of alternative polyadenylation sites. 2. When more than one splice
site is present within an exon, the exon length can vary due to the use of alternative 5’ and 3’ splice sites. Other
two less common splicing events are 3. mutually exclusive splicing, where one exon or the other is present in the
mature mRNA but not both and 4. intron retention (Baralle and Baralle, 2017).
and silencers (ISE and ISS, respectively) (Pagani and Baralle, 2004). Several common characteristics are
that these auxiliary sequences are short (less than 10 nt), their sequences are variable, most of the time
they are present in multiple copies and they are weakly active individually.
e vast majority of enhancer elements contain purine-rich sequences, which are binding sites for serine/arginine-
rich (SR) proteins (Long and Caceres, 2009). SR proteins are characterized by the presence of one or two
RNA recognition motifs (RRM) at the N-terminal and an arginine/serine (RS) domain at the C-terminal
(Manley and Krainer, 2010). Generally speaking, these proteins interact through their RS domains with
each other, with U1 snRNA, SR related proteins and with U2AF35, facilitating splicing by forming inter-
actions across exons and introns (Baralle and Baralle, 2017). Furthermore, it has also been observed that
enhancer activity can occur via recognition of SR proteins at ESE sites allowing the recruitment of the
spliceosome (U2 and U12) at the adjacent intron. ese proteins also act for the formation of complexes
B and C by promoting the incorporation of the tri-snRNP U4/U5/U6 and the binding between U2 and U6.
e silencer elements are principally bound by heterogeneous nuclear ribonucleoproteins (hnRNPs), which
bind pre-mRNA without necessarily forming stable association with other RNA-protein complexes. As
well as SR proteins, hnRNPs possess one or several RRM domains and one auxiliary domain implicated in
protein-protein interaction (Krecic and Swanson, 1999). At least 20 proteins are part of the family; they
are designated from A1 (34 Kda) to U (120 Kda). e mechanisms through which exonic and intronic
silencers interfere with splicing include inhibition of splice site recognition by sterically blocking the re-
cruitment of snRNPs (Tange et al., 2001). Some hnRNP such as hnRNPA1 may repress the splicing by
blocking the spliceosome assembly initial steps by the xation of several molecules all along the RNA on
specic or non-specic sequences (gure 1.15A). ey may also inhibit the eect of some nearby regu-
latory sequences (gure 1.15B). Finally, the repression of the splicing may be due to the formation of a
loop in the pre-mRNA preventing splicing machinery to recognize the exon site (Baralle and Baralle, 2017)
(gure 1.15C).
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Figure 1.15: Repressor role of hnRNP on splicing. A: Inhibition of spliceosome assembly by hnRNP polymeriza-
tion. B: Repression of U2 binding by steric hindrance. C: Inhibition of splicing by hnRNP dimerization and creation
of loop inside the pre-mRNA. Exons and introns are represented by gray rectangle and black horizontal bars, re-
spectively. hnRNP stands for heterogeneous nuclear ribonucleoproteins. SR stands for serine/arginine-rich proteins.
U2AF stands for U2AF stands for U2 snRNP auxiliary factor. snRNP U2 stands for the small nuclear ribonucleopro-
tein particles.
21
1.4. THE HERPESVIRIDAE FAMILY CHAPTER 1. INTRODUCTION
1.4 e Herpesviridae family
1.4.1 Nomenclature and classication
e order Herpesvirales contains three families: the Malacoherpesviridae infecting bivalves, the Alloher-
pesviridae infecting shes and amphibians and the Herpesviridae infecting mammals, birds and reptiles
(Davison, 2010) (gure 1.16). e family Herpesviridae is the largest and is composed of three subfamilies,
the alpha-, beta- and gammaherpesvirinae, classied according to their biological properties. is viral
family contains at present more than 130 species sharing common features (Ackermann, 2004; Davison
et al., 2009). ey are spherical viral particles measuring from 150 to 300 nm. ey possess a linear double
stranded DNA ranging from 124 to 230 kilobase pairs (kbp) accompanied by some rare RNA molecules
(Bechtel et al., 2005; Bresnahan and Shenk, 2000; Jochum et al., 2012). ese nucleic acids are associated
with an icosahedral capsid composed of 162 capsomers surrounded by proteins with regulatory functions
which constitutes the tegument. Finally the virus is covered by an envelope made from cellular membranes
and containing glycoproteins which spike on its surface (gure 1.17). Herpesviruses are also classied ac-
cording to their genome arrangement. Six sequence arrangements are described and are designated by
the leers A to F (gure 1.18).
is thesis focuses on an oncogenic herpesvirus from the Alphaherpesvirinae subfamily named gallid
herpesvirus-2 (GaHV-2). During this work, a very virulent strain of GaHV-2 was used (RB-1B strain),
Genbank n°EF523390 and its genome is 178.246 bp of length. is herpesvirus presents a genome arrange-
ment belonging to the E group (gure 1.19). Two unique sequences termed unique long (UL) and unique
short (US) are surrounded by inverted repeats namely terminal and internal repeat long (TRL/IRL) for
UL and internal and terminal repeat short (IRS/TRS) for US . Structural and conserved genes are mainly
encoded in UL and US regions whereas most genes involved in the latency and the transformation steps
are located in the repeated regions, such as latency associated transcript (LAT), the viral oncoprotein meq
and viral microRNAs (gure 1.19).
Besides these morphological properties, all family members of Herpesviridae family share several com-
mon biological properties (Ackermann, 2004). ey possess a large array of enzymes implicated in nucleic
acid metabolism (e.g., thymidine kinase), protein processing (e.g., protein kinase) and DNA synthesis (e.g.,
DNA polymerase, helicase) which occurs in the nucleus of infected cells. In addition, the production of
infectious progeny virus generally ends by the destruction of the infected cells. Following lytic infection,
herpesviruses systematically establish latency in their natural host in specic cell types.
e classication into three subfamilies was mainly established on the basis of the host range, but also on
the spectrum of cells capable of supporting viral latency in vivo (gure 1.16) (Davison et al., 2009).
Alphaherpesvirinae subfamily includes four genera designated Mardivirus, Iltovirus, Simplexvirus and the
Varicellovirus. Mardivirus and Iltovirus infect avian hosts while Simplexvirus andVaricellovirus infect mam-
malian hosts (Smith, 2012) (gure 1.16). Alphaherpesviruses are characterized by a broad host range, a
short replication cycle, a rapid proliferation in cell culture and for some of them an ecient lysis in infected
cells. Members of this subfamily mostly infect epithelial or neuronal cells before establishing latency
mainly in non-dividing sensory neurons. GaHV-2 from the Mardivirus genus is an oncogenic herpesvirus
causing the Marek’s disease (MD). Unlike most of the members of this subfamily, GaHV-2 latently infect
T CD4+ lymphocytes and is able to trigger tumor formation in avian species. Its biological properties
are closer from the members of the Gammaherpesvirinae than from the Alphaherpesvirinae (Osterrieder
et al., 2006). e main discriminative features of this alphaherpesvirus are that the replicative infection
does not lead to cell lysis and that intra host viral transmission is exclusively mediated through cell-to-cell
spreading.
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Figure 1.16: Herpesvirales order classication. Representative species are specied for each gender. GaHV for
gallid herpesvirus. HHV for human herpesvirus. MHV for murine herpesvirus. ElHV for elephantid herpesvirus.
HHV5 or human cytomegalovirus (HCMV)
Figure 1.17: Herpesvirus morphology. Schematic representation of a viral particle. e nucleocapsid is the as-
sociation of viral capsid proteins with viral nucleic acid. e capsid is composed of a major capsid protein named
viral protein 5 (VP5) and a triplex composed of VP23 and VP19C proteins. Around the nucleocapsid is found an
unorganized structure named tegument. is is composed of viral proteins. Finally, the virus is surrounded by an
envelope containing glycorpoteins. T stands for triangulation number.
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Figure 1.18: Genomic herpesvirus organization from group A to F. is schema represents the six genome
classes in Herpesviridae family. e unique regions are represented by horizontal lines and boxes represent the
repeated regions. In the A group LTR and RTR stand for Le Terminal Repeat and Right Terminal repeat. In the
B group terminal sequences are repeated with a variable number of repeats. e C group is composed of internal
domains from R1 to R4 and the D group shows internal and terminal repeated domain (IR and TR). e E group is
composed of two unique regions unique long (UL) and unique short (US) such as the D group. Each unique region
is surrounded by inverted repeats: UL is surrounded by the terminal repeat and the internal repeat long (TRL and
IRL) and US is surrounded by internal repeat and terminal repeat short (IRS and TRS). No repetition was found in
the F group.
Figure 1.19: Crucial factors implicated in tumorigenesis during GaHV-2 infection. UL and US represent
the long and the short unique regions, respectively. ey are surrounded by long and short terminal and internal
inverted repeats: TRL/IRL around UL and IRS/TRS around US . vTR stands for viral telomerase RNA. microRNAs
cluster are named cluster I, II and III. LAT stands for Latency Associated Transcript.
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Betaherpesvirinae subfamily is composed of four genera designated Cytomegalovirus, Muromegalovirus,
Roseolovirus and Proboscivirus (gure 1.16). ey are characterized by a narrower host range, a longer
multiplication cycle and a less pronounced proliferation in cell. ey establish latency essentially in se-
cretory glands, lymphoreticular cells and kidney in mammalian hosts (Bernard N Fields, 2007).
Finally, gammaherpesvirinae subfamily contains also four genera: Lymphocryptovirus, Rhadinovirus, Per-
cavirus standing for perissodactyl and carnivore and Macavirus standing for malignant catarrhal fever.
ey latently infect monocytes, dendritic cells and usually either B or T lymphocytes in mammalian hosts
(gure 1.16) (Dupuy et al., 2012). Under specic circumstances, they are also able to transform latently
infected cells and induce lymphoproliferative disease and/or other non-lymphoid cancers in their infected
hosts.
1.4.2 Viral replicative cycle
Productive infection
e multiplication cycle is similar in all members of the group (gure 1.20). Viral life cycle begins with
the entry into the cell with a rst reversible aachment between viral glycoproteins (gC and gB) and cel-
lular glycosaminoglycans at the cell surface (Herold et al., 1991). ereaer a stable aachment is made
possible with the viral glycoprotein gD interacting with cellular receptors such as tumor necrosis factor
superfamily, cell adhesion molecules of the immunoglobulin superfamily and 3-O-sulphated heparan sul-
fate (Krummenacher et al., 2005; Donnell et al., 2006; Meenleiter et al., 2009). is stronger interaction
induces fusion of the viral envelope with the cellular membrane, leading to the release of proteins from
the tegument into the cytoplasm. Two mechanisms of entry are described (Connolly et al., 2011). First, the
entry might be performed by the fusion of the viral envelope with the cellular plasma membrane. Second,
the entry is possible by endocytosis of the viral particle followed by fusion of the endosomal membrane
with the viral envelope. Once inside the cytoplasm, the released nucleocapsid travels along microtubules
to the nuclear pore where viral DNA is transferred into the nucleus (Meenleiter et al., 2009). is phe-
nomenon implies the dynein/dynactin protein motor (Sodeik et al., 1997). In the nucleus the viral genome
circularizes. In this form, it triggers the initiation of viral genes transcription in three sequential phases
by the cellular RNA polymerase II. e rst phase of transcription is initiated by the regulatory tegument
proteins and allows the transcription of genes called “immediate early” (IE) or α. One important tegument
protein implicated in transcription is VP16 wich is part of a protein complex containing two cellular fac-
tors (cellular octamer DNA binding protein (Oct1) and HCF) (Wysocka and Herr, 2003). Once translated,
these IE proteins mainly act as transactivators of transcription. ey stimulate the transcription of the
“early” genes (E) or β. ese genes are requested for DNA replication. e last phase, named late “L” or γ,
leads to the synthesis of structural proteins such as the envelope glycoproteins and the capsid proteins. L
genes are transcribed aer DNA replication. e synthesis of viral genome occurs through the mechanism
of “rolling circle” generating units consisting of concatemeric structures separated by sequences that are
specically targeted for enzymatic cleavage and packaging (Nicoll et al., 2012). e cleavage results in the
insertion of one copy of the viral genome during encapsidation.
Finally, virus assembly and egress take place in order to infect neighboring cells. Late proteins, re-
quested to form the icosahedral capsid, are transported into the nucleus via the nuclear localization signal
(NLS) and assemble by an autocatalytic process regulated by the viral protease (Heming et al., 2017).
Nucleocapsid egress from the nucleus to the cytoplasm is still a maer of debate. Several mechanisms
have been proposed : the model of nuclear pore egress, the “luminal” model and nally the “envelop-
ment/deenvelopment/reenvelopment” model (gure 1.21) (Meenleiter and Minson, 2006). e most likely
one being the latest. According to this model, the mature capsid buds into the inner nuclear membrane
(primary envelopment). Pre-enveloped viruses are then localized between the inner and the outer nuclear
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Figure 1.20: Schematic representation of herpesvirus replicative cycle. Grey triangles represent viral glyco-
proteins. VP stands for viral protein. α RNA stands for immediate early RNAs. β RNA stands for early RNAs. γ
RNA stands for late RNAs. (created from (Roizman and Whitley, 2001)).
membrane. e primary envelope is acquired during budding through the inner nuclear membrane and is
then lost by fusion of this membrane with the outer nuclear membrane (de-envelopment) leading to the
release of the nude capsid in the cytoplasm (Meenleiter et al., 2009). e naked capsid will re-envelop by
budding into the Golgi compartment. e mature enveloped particle is eventually secreted by exocytosis
from the infected cell (gure 1.21) (Meenleiter, 2002; Meenleiter and Minson, 2006).
Latent infection
Latency is a hallmark of the herpesvirus life cycle. It is described as the maintenance of the virus in the
host cell in the absence of progeny virus production. During latency only a small subset of viral genes
are expressed and the viral genome generally persists as episome in the nucleus of infected cells. In
dividing cells, the viral genome replicates simultaneously with the cellular DNA and viral episomes are
distributed equally between daughter cells (Vogel et al., 2010). For some herpesviruses such as GaHV-
2 and HHV-6, viral genomes integrate into the host genome. All along latency herpesviruses are able
to undergo reactivation that ultimately results in a new production of viral particles. Furthermore, some
herpesviruses fromAlphaherpesvirinae (gallid Herpesvitrus-2 (GaHV-2)) andGammaherpesvirinae (Human
HerpesVirus-4 (HHV-4) and HHV-8) subfamilies are associated with tumorigenesis during latency in their
natural hosts.
Viral and cellular factors associated to latency establishment are numerous and not yet all identied. Some
might trigger oncogenesis as an unwanted eect during infection. ese factors regulation and implication
during GaHV-2 infection form the subject of the following chapter.
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Figure 1.21: Herpesvirus egress model. e grey triangles represent viral glycoproteins anchor at the viral en-
velop. e hexagon represents the viral capsid. Grey vesicle represents the golgi apparatus and the trans-golgi
network.
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1.5 Marek’s disease : genetic regulation of gallid herpesvirus 2
infection and latency (updated from Gennart et al., 2015)
Abstract
gallid herpesvirus-2 (GaHV-2) is an oncogenic alphaherpesvirus that causes Marek’s
disease (MD), a T cell lymphosarcoma (lymphoma) of domestic fowl (chickens). e
GaHV-2 genome integrates by homologous recombination into the host genome and,
by modulating expression of viral and cellular genes, induces transformation of la-
tently infected cells. MD is a unique model of viral oncogenesis. Mechanisms im-
plicated in the regulation of viral and cellular genes during GaHV-2 infection oper-
ate at transcriptional, posranscriptional and post-translational levels, with involve-
ment of viral and cellular transcription factors, along with epigenetic modications,
alternative splicing, microRNAs and post-translational modications of viral pro-
teins. Meq, the major oncogenic protein of GaHV-2, is a viral transcription factor
that modulates expression of viral genes, for example by binding to the viral bidi-
rectional promoter of the pp38-pp24/1.8 kb mRNA, and also modulates expression
of cellular genes, such as bcl-2 and matrix metalloproteinase 3 (mmp-3). GaHV-2
expresses viral telomerase RNA subunit (vTR), which forms a complex with the cel-
lular telomerase reverse transcriptase (TERT), thus contributing to tumorigenesis,
while vTR independent of telomerase activity is implicated in metastasis. Expression
of a viral interleukin 8 homologue may contribute to lymphomagenesis. Inhibition
of expression of the pro-apoptotic factors JARID2 and SMAD2 by viral microRNAs
may promote the survival and proliferation of GaHV-2 latently infected cells, thus
enhancing tumorigenesis, while inhibition of interleukin 8 by viral microRNAs may
be involved in evasion of immune surveillance. Viral envelope glycoproteins derived
from glycoprotein B (gp60 and gp49), as well as glycoprotein C, may also play a role
in immune evasion.
1.5.1 Introduction
Marek’s disease (MD) is a contagious lymphoproliferative disease of domestic fowl (chickens) rst de-
scribed in 1907 by Jozsef Marek. e disease is caused by an oncogenic alphaherpesvirus, gallid herpesvirus
type 2 (GaHV-2), and is characterized by formation of T cell lymphosarcomas (lymphomas) and paralysis
(Burgess et al., 2004). MD is present worldwide and has a major economic impact on the poultry industry.
Until the 1950s, the disease was associated with a polyneuritis syndrome, with a low rate of mortality
(gure 1.22). Concomitant with increasing industrialisation in the 1960s, an acute form of the disease ap-
peared, with a higher mortality rate (10–30 %) (Biggs and Nair, 2012). is acute form was characterized
by visceral tumors in addition to nervous system lesions described initially. In the classical (paralytic)
form, the disease has an incubation time of 3–9 weeks. e rst clinical signs are locomotor dysfunction,
followed by the onset of paralysis; the chicken usually dies of starvation (Mazzella et al., 1986). e acute
(lymphomatous) form leads to the death of the chicken aer 4 weeks and is characterized by multiple T
cell tumors arising in visceral organs.
In the late 1960s, GaHV-2, also known as MD virus type 1 (MDV-1), was identied as the causative agent
of MD (Churchill and Biggs, 1967). Currently, herpesviruses belonging to the gender Mardivirus are di-
vided into three viral species, designated GaHV-2, GaHV-3 and meleagrid herpesvirus type 1 (MeVH-1)
(Table 1.2) (Bulow and Biggs, 1975a,b). e GaHV-2 group contains all the oncogenic viruses and includes
four pathotypes: moderate (m; strain CU-2), virulent (v; strain HPRS-16), very virulent (vv; strains RB-1B
or Md5) and very virulent + (vv+; strain RK-1) (Wier, 1997).
In the late 1960s, two vaccines against MD were generated; the rst was based on the GaHV-2 oncogenic
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Figure 1.22: Time line representing the history of increase virulence and usage of vaccine against gallid
herpesvirus-2 (GaHV-2). Black bars represent every 20 years. MeHV for meleagrid herpesvirus.
strain HPRS-16, aenuated by more than 30 passages in chicken kidney cell cultures (Table 1.2) (Churchill
and Chubb, 1969). A few years later, this vaccine was replaced by a vaccine based on MeHV-1 (strain
FC-126) (Table 1.2). Since vaccine failures were still encountered when using HPRS-16 or FC-126, a new
vaccine was developed based on a naturally aenuated GaHV-2 strain, CVI988-Rispens, which exhibits
low pathogenicity (Table 1.2). In the 1980s, the virulence of GaHV-2 increased further with the emergence
of a vv strain. e vaccine strategy was modied; a bivalent vaccine composed of FC-126 (MeHV-1) and
SB-1 (GaHV-3) was introduced (Table 1.2) (Calnek et al., 1982; Wier and Lee, 1984). Ten years later, there
was a further increase in the incidence of MD due to the emergence of hypervirulent (vv+) GaHV-2 (
Table 1.2). In response, the three species of Mardivirus were combined into a trivalent vaccine composed
of CVI988 (GaHV-2), SB-1 (GaHV-3) and FC-126 (MeVH-1). Currently, the disease is controlled with this
updated vaccine strategy. Vaccination prevents the development of MD, but not virus transmission or
infection, so there is a risk that increases in virulence may occur in the future (Read et al., 2015). New
strategies, such as recombinant virus, e.g. GaHV-2 ∆ Marek EcoQ (Meq), might be needed in the future
to control infection (Lee et al., 2008, 2012).
e aim of this review is to examine the genetic regulation of viral and cellular genes during the infectious
cycle of GaHV-2 and to explore how the virus modulates gene expression.
Table 1.2: Description of the genderMardivirus
Genotype Pathotype Oncogenicity Strains
GaHV-2 (MDV-1) Hypervirulent (vv+) +++ RK-1, 584A, 648A
Very virulent (vv) ++ RB-1B, Md5, Md-11
Virulent (v) + GA, HPRS-16, JM
Moderate (m) No Rispens, CU-2, HPRS17
GaHV-3 (MDV-2) Moderate (m) No SB-1, HPRS-24, HN-1
MeHV-1 (MDV-3) Moderate (m) No FC-126, WTHV, HPRS-26
Table notes: GaHV for gallid herpesvirus. MeHV, meleagrid herpesvirus.
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1.5.2 Infectious cycle of gallid herpesvirus type 2 in vivo
e infectious cycle of GaHV-2 contains four phases: (1) the early productive phase; (2) the latent phase;
(3) the late productive phase; and (4) the transformation phase (gure 1.23). Infection begins by inhalation
of dust or dander containing infectious particles released from feather follicles. Within the lung, the virus
is phagocytosed by macrophages and transported to secondary lymphoid tissue, such as the spleen, thy-
mus and bursa of Fabricius (Barrow et al., 2003). In these organs, the early productive phase, with active
replication of virus, takes place mainly in B lymphocytes (Shek et al., 1983). e virus then transferred
via cell-to-cell spread to neighboring cells in which latency is established. In the latent phase, the virus
persists in target cells, mainly CD4+ T lymphocytes, without replicating; genome expression is limited to
specic genes required to maintain latency, no progeny virions are produced and the latent virus remains
undetected by the immune system (Davison and Nair, 2004). e GaHV-2 genome integrates by homolo-
gous recombination into the host genome within specic telomeric regions in chromosomes of any size
(macro- and micro-chromosomes) (Robinson et al., 2010). e GaHV-2 linear genome possesses telomeric
repeats identical to host telomere sequences (TTAGGG)n (Kaufer et al., 2011). Viral integration appears to
enhance cellular transformation and tumor formation. e late productive phase consists of reactivation
of the virus in a subpopulation of latently infected cells (gure 1.23). During this phase, viral replication
occurs within epithelial cells in feather follicles and is associated with horizontal transmission of the virus.
Finally, the transformation phase appears within latently infected cells, which spread in peripheral nerves
and visceral organs, causing T cell lymphoma and paralysis (Davison and Nair, 2004).
During the viral replication cycle, transcriptional modication and epigenetic changes (DNAmethylation,
histone post-translational modications and non-coding RNAs), along with post-transcriptional and post-
translational modications, regulate expression of cellular and viral genes (gure 1.24). ese allow GaHV-
2 to switch between the productive and latent phases, and to induce transformation of infected cells.
1.5.3 Transcriptional modication in GaHV-2 infected cells
Transcriptional regulation by the oncoprotein Meq
During GaHV-2 infection, some latently infected T cells undergo transformation and form generalized T
lymphomas in chickens. Meq, a nuclear phosphoprotein of 339 amino acids (aa), is expressed in the lytic
and latency phases and is considered to be the major oncogenic protein of GaHV-2. e gene encodingmeq
is localized within the repeat regions surrounding the long unique region of the GaHV-2 genome, known
as the terminal and internal repeats of the unique long region (TRL and IRL, respectively) (Qian et al.,
1995). e C-terminal region is a proline-rich region with a transactivation domain (gure 1.25 A) (Qian
et al., 1995, 1996). Its N-terminal region possesses a basic-leucine zipper (bZIP) structure similar to that
of the cellular transcription factors (proto-oncogenes) c-Jun/c-Fos (gure 1.25 A) (Qian et al., 1995, 1996).
is bZIP domain allows Meq to form homodimers or to dimerize with other proteins possessing a bZIP
domain, such as c-Jun, for which it has a strong anity (Levy et al., 2003). Meq is also able to bind to cel-
lular factors, such as c-AMP response element-binding protein (CREB), musculoaponeurotic brosarcoma
oncogene homologue (MAF), sucrose non-fermentable (SNF) and activating transcription factors (ATFs)
1, 2 and 3 (Liu and Kung, 2000; Levy et al., 2003), p53, retinoblastoma protein (pRB), cyclin-dependent
kinase 2 (CDK2), infected cell protein 4 (ICP4) (Liu and Kung, 2000) and COOH terminal-binding protein
(CtBP) (Brown et al., 2005). e heterodimer Meq/Jun and the homodimer Meq/Meq bind to specic nu-
cleotide sequences, designated the Meq responsive element I (MERE I, 5’ -GAGTGATGACGTCATC- 3’)
and MERE II (5’ -ACACACA- 3’), respectively (gure 1.25 B). MERE I sites are found in viral promoters,
such as ICP4, a transactivator of the replicative phase, and glycoprotein B (gB), along with cellular pro-
moters, including interleukin (IL)-2, B cell lymphoma 2 (Bcl-2), matrix metallo-proteinase-3 (MMP-3) and
gga-miR-21 promoters (gure 1.25 B) (Qian et al., 1995; Levy et al., 2003, 2005; Ajithdoss et al., 2009; Stik
et al., 2013). e binding of Meq/c-Jun to MERE I activates transcription of genes that have roles asso-
ciated with cell transformation and viral replication. GaHV-2 transforms latently infected cells through
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Figure 1.23: e dierent infection phases of the oncogenic strain gallid herpesvirus-2 (GaHV-2). e
number of days (D) in this diagram was derived from experimental observations (natural infection is slower). Day 0
represents the day of the inhalation of the viral particle in the lung followed by its migration to lymphoid organs. e
darker light grey arrows represent the reactivation of the virus from latently infected T-cells. At around 14 days post-
infection, infectious particles are detected in dust from feather follicles. At the late productive phase, viral replication
in feather follicle epithelium (FFE) is fully productive; enveloped, infectious and cell-free viruses are released in the
environment (horizontal dissemination). B surrounded with a round represent B lymphocytes. T surrounded with a
round represent latently infected T lymphocytes. T surrounded with a star represent T lymphocytes infected with
reactivated viruses. Dark grey rounds represent transformed latently infected T cells.
Figure 1.24: Overview of genetic regulation of gallid herpesvirus -2 (GaHV-2) infection. (a) Transcriptional
level. (b) Early post-transcriptional level. (c) Late post-transcriptional level. (d) Post-translational modication. Each
modication level comprises one or multiple examples of factors implicated in the modication of gene expression
(black frame).
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activation of gene expression of bcl-2, which is anti-apoptotic and facilitates cell survival, and the enzyme
MMP-3, which degrades the extracellular matrix, facilitating dispersion of transformed cells. e cellular
micro-RNA (miRNA) gga-miR-21 is also implicated in transformation; it targets tumor suppressor genes,
such as programmed death cell 4 (pdcd4), a protein implicated in apoptosis (Meng et al., 2007; Asangani
et al., 2008). At another level, Meq regulates viral replication through activation of ICP4, implicated in
viral replication, and gB, implicated in cell-to-cell spread of GaHV-2 in cultured cells (Schumacher et al.,
2000; Levy et al., 2003).
Although gene expression is enhanced aer binding of the Meq/c-Jun heterodimer to the MERE I site,
the binding of the homodimer Meq/Meq to MERE II represses gene expression. A MERE II site has been
localized in the viral bidirectional promoter controlling on one hand the pp38-pp24 genes and on the other
hand the 1,8 Kb mRNA (Qian et al., 1996; Liu and Kung, 2000; Levy et al., 2003). Since pp38 and pp24 are
late lytic proteins, Meq prevents viral DNA replication and productive infection by targeting this promoter
(gure 1.26). e heterodimer pp38/pp24 also targets its own promoter (gure 1.26) (Jiabo et al., 2008);
pp38 is located at the IRL/UL junction, with its 5’ end in UL, while pp24 is located at the TRL junction
with its 3’ and in UL. e pp38 and pp24 proteins have their N-terminal extremity in common (Shigekane
et al., 1999). e binding of the heterodimer pp38/pp24 induces upregulation of the bidirectional promoter
(Shigekane et al., 1999; Chen et al., 2009). In this condition, a 14 kDa protein is encoded by the 1.8 kb
mRNA. is protein promotes the transition from G1 to S phases of the cell cycle and enhances viral DNA
replication (Hayashi et al., 1999). In addition, pp38 is involved in lytic infection of B lymphocytes in the
spleen and maintains the viability of infected T lymphocytes by limiting apoptosis (Gimeno et al., 2005).
Increased activity of the bidirectional promoter is associated with immortalization and proliferation of
latently infected cells.
Transcriptional regulation of the GaHV-2 viral promoter by cellular transcription factors
Cellular transcription factors, such as p53 and c-Myc, bind to and modulate the expression of viral genes,
such as the latency associated transcripts (LATs) and viral telomerase RNA subunit (vTR) (Shkreli et al.,
2007; Stik et al., 2010). LATs are long, non-coding, RNAs (10 kb) localized in the internal and terminal
repeats of the unique short region (IRS/TRS) of the GaHV-2 genome. ese non-coding RNAs are mainly
expressed during viral latency and lymphomagenesis, suggesting that LATs have a role in the maintenance
of latency and/or cell transformation. A cluster of microRNAs (cluster III, designated the MDV-1-miRM8-
M10 cluster) has been identied in the rst intron of the LATs gene (miR-M8, miR-M13, miR-M6, miR-M7
and miR-M10) (Burnside et al., 2006; Strassheim et al., 2012). ese miRNAs are overexpressed in GaHV-2
transformed cells and in latently infected cells (Stik et al., 2010). is overexpression is due to the binding
of p53, a tumor suppressor, to the LATs promoter, which consists of a series of 60 bp repeats. Each of the
repeats contains a conserved functional p53 binding site. e number of 60 bp repeats varies according to
strain of virus and may be associated with the level of virulence (gure 1.27) (Spatz and Silva, 2007; Stik
et al., 2010).
e cellular proto-oncogene c-Myc induces expression of the vTR promoter (Shkreli et al., 2007). e
telomerase complex is composed of two subunits: telomerase reverse transcriptase (TERT), which has
telomerase activity, and telomerase RNA (TR), which is recognized by TERT and is used as a template to
copy the repeat motif at the end of the chromosome (Chbab et al., 2010). GaHV-2 is the only virus known
to encode a vTR (Fragnet et al., 2003). is RNA component is functional when it associates with chicken
TERT and is expressed at a higher level than its avian homologue, chicken TR (Fragnet et al., 2005; Shkreli
et al., 2007). e vTR/chTERT complex contributes to the establishment and maintenance of GaHV-2
induced tumorigenesis (Trapp et al., 2006), while vTR independent of telomerase activity is implicated in
metastasis (Kaufer et al., 2010). e vTR gene is regulated indirectly by Meq; the Meq/c-Jun heterodimer
binds to and induces expression of the c-myc promoter, then c-Myc transactivates vTR (gure 1.25) (Levy
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Figure 1.25: e oncoprotein Meq is a transcriptional factor encoded by gallid herpesvirus-2 (GaHV-2). A:
e bZIP domain has homology with the basic leucine zipper domain (bZIP) of the cellular transcription factors
c-Jun and c-Fos, which mediates dimerization. e transactivation domain is a proline-rich domain triggering ei-
ther activation or repression of the promoter activity. B: Meq can form heterodimers (Meq/c-Jun) or homodimers
(Meq/Meq), which bind to Meq response element I (MERE I) and MERE II, respectively. Binding of Meq/c-Jun to
viral and cellular promoters promotes gene transcription, while the binding of Meq/Meq represses gene expression.
ICP4 for infected cell protein 4. gB for glycoprotein B. Il-2 for interleukin 2. Bcl-2 for B cell lymphoma 2. MMP-3
for matrix metalloproteinase 3. Gga-miR-21 for chicken microRNA-21. pp38 for phosphoprotein.
Figure 1.26: Dual functioning of the bidirectional promoter pp38-pp24/1.8 kb mRNA by binding of viral
transcription factors. e grey squares represent the oncoprotein Meq. e black circle represents the late lytic
protein pp38 and the light grey circle represents the late lytic protein pp24. + for positive regulation on the promoter
activity allowing gene expression. – for negative regulation on the promoter activity generating repression of gene
expression.
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Figure 1.27: Alignment of genomic regions containing 60 base pair (bp) repeats in the latency associated
transcript (LAT) promoter in dierent gallid herpesvirus type 2 (GaHV-2) strains. White boxes represent
repeat motifs of 60 nucleotides. e black box upstream represents the sequence localized between telomeres and
the 60 nucleotide repeat motif. e dierent strains are ranged by pathotype: avirulent (a), moderate (m), virulent
(v), very virulent (vv) and hypervirulent (vv+) (adapted from (Spatz and Silva, 2007)).
et al., 2005; Shkreli et al., 2007).
Transcriptional regulation by epigenetic modication
Epigenetic is the study of heritable DNA structure modication without alteration of sequence. is im-
plies a regulation of gene expression during development and in embryonic cells (Mason et al., 2012). ese
modications on genomes are involved in normal development as well as in disease like cancer or neu-
rological disorder (Moore et al., 2013). Epigenetic marks include histone post-translational modications
(HPTMs), DNA methylation (DNAme) and the long non coding RNA recently described as triggers of the
processes (Harries, 2012). Epigenetic modications are implicated in the modulation of viral gene expres-
sion during GaHV-2 infection and contribute to the switch from latency to the lytic phase (gure 1.24).
e GaHV-2 genome is methylated during latency, suggesting that methylation restricts gene expression
during the latent phase (Kanamori et al., 1987). In a study of repeat regions of the GaHV-2 genome, a
region encoding the lytic phase protein pp38 was more methylated than a neighboring region encoding
latent phase transcripts (LATs and Meq) (Brown et al., 2012). In the same study when GaHV-2 promoters
were analyzed during latency, the region containing the pp38 (lytic) promoter and the origin of replica-
tion (ori) where shown to possess restrictive marks of epigenetic modication, such as histone 3 lysine
27 trimethylation (H3K27me3) and H3K9me3, while the region containing the microRNA-M9/M4 cluster,
meq and LATs (latent) promoters possessed permissive marks, such as H3K4me3 and H3K9 acetylation
(H3K9Ac) Table 1.3 (Brown et al., 2012). Recently, two studies demonstrated a dierential DNA methyla-
tion paern at promoters of two immediate early genes, ICP4 and ICP27 (Strassheim et al., 2016; Rasschaert
et al., 2018). Each of these viral genes possesses two alternative promoters: a proximal and a distal one.
e research was undertaken in three cell types representing the productive, the latent and the reactiva-
tion phase. For ICP4, the distal promoter is associated with its expression during the productive and the
latent phases, whereas the proximal promoter is associated with its expression during the reactivation
phase. Both promoters are regulated by DNA methylation during the viral life cycle and are hypermethy-
lated during latency (Rasschaert et al., 2018). Description of the ICP27 transcripts showed that this gene
transcribed either by its own promoter (pICP27) or by the glycoprotein K promoter (pgK). e pgK can
generate a spliced ICP27 transcript giving an N-terminal-deleted ICP27 isoform (ICP27delatN). e pICP27
is essentially active during the productive phase and is associated with a low level of DNA methylation
(Strassheim et al., 2016). e alternative promoter, pgK, preferentially generates the gK transcript during
the productive phase and the ICP27deltaN during the latent phase. DNA methylation analysis showed
that pgK was systematically demethylated (Strassheim et al., 2016). Altogether these data indicate that
DNAme and HPTMs may play a role in the restriction of specic genes during the GaHV-2 replication
cycle, but further investigation is needed.
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Epigenetic changes play a role in regulating DNA replication and virus reactivation in other herpesviruses
(Table 1.3). Only HPTMs have been found during infection with the alphaherpesviruses human herpesvirus-
1 (HHV-1, herpes simplex virus type 1) and HHV-3 (varicella-zoster virus) (Liang et al., 2009) while both
DNA methylation (DNAme) and histone post-translational modications (HPTMs) have been observed
during HHV-4 and HHV-8 (Epstein–Barr virus and Kaposi’s sarcoma associated virus; gammaherpesvirus)
infections (Table 1.3) (Murata and Tsurumi, 2013, 2014; Kuss-duerkop et al., 2018). HHV-8 induces dierent
cancers such as kaposi’s sarcoma, primary eusion lymphomas (PEL) and multicentric castleman disease.
Oncogenesis processes were observed in endothelial cells and in B cells with activation of angiogenesis
by viral miRNAs and oncoproteins such as Latency associated nuclear antigen (LANA) (Purushothaman
et al., 2016). LANA is expressed in HHV-8 positive cancer and is known to induce angiogenesis and ac-
tivates host cell cycle by degrading p53 and by stabilizing c-myc (Wei et al., 2016). LANA was observed
to interact with DNMTs and recruit DNMT3A at host chromatin (Shamay et al., 2006) inducing hyper-
methylation at specic host promoters such as transforming growth factor β (TGF-β) type II receptor
(TβRII). is hypermethylation inhibits TβRII expression and lead to KSHV-induced PEL development
(Bartolo et al., 2008). e TGF-β pathway is implicated in development, cell proliferation, dierentiation,
apoptosis and homeostasis (Mishra et al., 2007; Massague´ et al., 2000). Deregulation of this pathway may
lead to cancer development and progression (Colak and Dijke, 2017). Moreover, another viral protein of
HHV8 (viral interleukin-6 (vIL-6)) enhances DNMT1 expression triggering global hypermethylation in
endothelial cells leading to cell proliferation and migration (Wu et al., 2014). Epigenetic changes were
also observed on latent and lytic genes during viral life cycle of HHV-8 (Table 1.3) (Gu¨nther and Grund-
ho, 2010; Purushothaman et al., 2016). During latency, negative marks such as hypermethylation and
H3K27me3 were observed at promoters of lytic genes (Purushothaman et al., 2016). An example, is the
repression by hypermethylation of the immediate early gene promoter RTA during latency. e viral pro-
tein LANA was shown to recruit EZH2, a methyltransferase which triggers H3K27me3, on lytic promoter
during latency (Purushothaman et al., 2016).
HHV-4 induces dierent B cell lymphomas (Burki’s and Hodgkin’s lymphomas) but also carcinomas of
nasopharynx (NPC) and stomach (Li et al., 2016). Several miRNAs and proteins were shown to enhance B
cells and epithelial cells transformation such as latent membrane proteins (LMP) 1 and 2 which activate
oncogenic pathways (Raab-traub, 2012). EBV possesses three latency stages and according to these stages
dierent DNMTs are overexpressed. In EBV associated gastric cancer (EBVaGC) latency I, LMP2A trans-
activates DNMT1 and DNMT3B (Hino et al., 2009). In EBV associated NPC (latency II), LMP1 enhances
transcription of DNMT1, DNMT3A and DNMT3B (Tsai et al., 2006). In hodgkin’s lymphoma cell lines (la-
tency II) as well as in lymphoblastoid cell lines derived from EBV positive germinal center B cells (latency
III), DNMT3A is overexpressed but the viral protein implicated in this overexpression was not identied
(Leonard et al., 2011). ese overexpression of DNMTs lead to hypermethylation of specic host promoter
such as IFN regulatory factor 5 (IRF5) in Burki’s lymphoma and EBVaGC (Yamashita et al., 2010). A re-
pression of IRF5 was also observed in breast cancer tissues. e repression of IRF5 due to EBV mediated
methylation gives a role in host immune invasion during viral persistence and oncogenesis. A summary
of epigenetic changes of these two gammaherpesviruses (HHV4 and 8) is related in Table 1.3.
e alteration of epigenetic mechanisms induced by DNA viruses are still an understudied eld. Proteins
implicated in these aberrant epigenetic paerns are not fully known. e results presented above suggest
that DNA viruses trigger repression of host gene expression by epigenetic marks in order to facilitate
persistent viral infection and to promote virus-induced cancer progression. Viruses are able to hijack dif-
ferent epigenetic mechanisms (DNA methylation and HPTMs) at specic host promoters. Many questions
remain about how viruses interfere with host epigenetic machinery.
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1.5.4 Early post-transcriptional modication: splicing
In GaHV-2, an immediate early protein, ICP27, prevents the splicing of a viral (viral interleukin 8, vIL-8)
and a cellular (chicken telomerase reverse transcriptase, chTERT) mRNA by interaction with serine/arginine
dipeptide rich (SR) proteins, which promote splicing by regulating splice site selection and spliceosome
assembly (Table 1.4) (Amor et al., 2011). Repression of chTERT splicing might have an eect during the
lytic and reactivation stages, when chTERT activity is low (Amor et al., 2011). Deletion of vIL-8 impairs
tumor formation in GaHV-2 infected chickens (Engel et al., 2012). vIL-8 is able to bind and aract B cells
(the main target during the lytic phase) and T cells (the main target during latency and transformation)
(Engel et al., 2012; Haertle et al., 2017). Inhibition of vIL-8 may slows down the GaHV-2 replicative cycle.
Dierent transcript isoforms have been observed during the latent and lytic phases of GaHV-2. During
latency, the cluster miR-M9-M4 forms a long spliced transcript containing the sequences encoding Meq
and vIL-8 (Coupeau et al., 2012). During the lytic phase, miR-M9-M4, Meq and vIL-8 are expressed as
three independent and unspliced transcripts (Coupeau et al., 2012). vIL-8 is also encoded by other splice
variants; two splice variants containing exon II and III of vIL-8 with either RLORF5a or RLORF4 were
observed 4 days post-infection (Jarosinski and Schat, 2007).
Numerous herpesviruses modulate the splicing of viral and/or cellular pre-mRNA, positively or negatively,
allowing the viruses to switch from latent to lytic phases and to escape from the immune system (Table 1.4).
ese herpesviruses are mainly alphaherpesviruses (HHV-1 and HHV-2) and gammaherpesviruses (HHV-
4 and HHV-8) (Hardwicket and Sandri-goldin, 1994; Hardy and Sandri-Goldin, 1994; Ruvolo et al., 2004;
Majerciak et al., 2008; Sedlackova et al., 2008; Nojima et al., 2009; Amor et al., 2011; Tang et al., 2013).
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CHAPTER 1. INTRODUCTION 1.5. MAREK’S DISEASE
1.5.5 Late post-transcriptional modication: microRNAs
Twenty-ve mature miRNAs from 13 pre-miRNAs have been identied in GaHV-2 (Burnside et al., 2006,
2008; Yao et al., 2009; Muylkens et al., 2010; Stik et al., 2014). ese 25 mature miRNAs are expressed
from three clusters located in repeat regions (IRL/TRL and IRS /TRS). Cluster I (MDV-1-miR-M9-M4) is
located upstream of the oncogene meq, while cluster II (MDV-1-miR-M11-M1) is located downstream of
meq. Cluster I is composed of six pre-miRNAs (miR-M9, miR-M5, miR-M12, miR-M3, miR-M2 and miR-
M4), while cluster II is composed of three pre-miRs (miR-M11, miR-M31 and miR-M1) (Burnside et al.,
2008). Cluster III (MDV-1-miR-M8-M10), located in short repeat regions (IRS/TRS), is situated in the rst
intron of the LATs gene. Most of GaHV-2 miRs are overexpressed during virus induced oncogenesis and
in transformed T cell lines (Stik et al., 2014).
Functional GaHV-2 microRNAs in the regulation of the cell cycle
e MDV-1-miR-M4-5p (cluster I) exhibits the highest expression during GaHV-2 lymphomagenesis (Muylkens
et al., 2010). is miRNA is implicated in GaHV-2 lymphomagenesis (Zhao et al., 2009; Muylkens et al.,
2010; Parnas et al., 2014; Yao and Nair, 2014). MDV-1-miR-M4-5p has the same seed region as miR-155,
an oncogenic cellular miRNA (gga-miR-155) (Zhao et al., 2009; Muylkens et al., 2010). Expression of miR-
155 has been associated with several human cancers (Yao and Nair, 2014). In GaHV-2 transformed cell
lines and GaHV-2 induced lymphoma, gga-miR-155 is downregulated, while MDV-1-miR-M4-5p is upreg-
ulated (Muylkens et al., 2010); MDV-1-miR-M4-5p may substitute for gga-miR-155 during latent infection
with GaHV-2. A common cellular target of these orthologous miRNAs is the histone methyltransferase
jumonji AT rich interactive domain 2 (jarid2), which promotes apoptosis; inhibition of jarid2 by MDV-1-
miR-M4-5p may promote the survival and proliferation of GaHV-2 latently infected cells, thus enhancing
tumorigenesis (gure 1.28) (Parnas et al., 2014).
ree other miRNAs from cluster I (MDV-1-miR-M3-5p, MDV-1-miR-M2-3p and MDV-1-miR-M9-5p) tar-
get cellular mRNA during GaHV-2 infection. MDV-1-miR-M3-5p targets smad2, which promotes apopto-
sis (Xu et al., 2011); inhibition of smad2 may promote the survival of GaHV-2 latently infected cells and
the formation of tumors (gure 1.28). MDV-1-miR-M2-3p and miR-M9-5p target the IL-18 mRNA (Par-
nas et al., 2014); IL-18 is a pro-inammatory cytokine stimulating interferon γ production by T cells and
inhibition of this cytokine may allow the virus to escape from immune surveillance (gure 1.28).
Functional GaHV-2 microRNAs in the regulation of the viral replication cycle
Pre-MDV-1-miR-M4 generates two mature miRNAs (MDV-1- miR-M4-5p and MDV-1-miR-M4-3p), which
target viral proteins, inhibiting expression of ul28 and ul32, respectively (Muylkens et al., 2010) (g-
ure 1.28); UL28 and UL32 are implicated in viral DNA cleavage and packaging, so their inhibition may
help to maintain latency. MDV-1-miR-M7-5p (cluster III) targets the coding region of two viral imme-
diate early (IE) mRNAs, icp27 and icp4 (Strassheim et al., 2012). Along with ICP22, ICP27 and ICP4 are
the rst proteins expressed during lytic infection; they trigger expression of early (E) and late viral genes
(Strassheim et al., 2012). Overexpression of this miRNA may promote establishment of the latent phase.
Altered regulation of cellular microRNAs
Expression of some cellular miRNAs is modulated during GaHV-2 infection and may play a role in tumori-
genesis (Table 1.5) (Yao et al., 2009; Stik et al., 2013; Tian et al., 2012). ese three studies assessed the over-
or under-expression of several cellular miRNAs in in vivo and in vitro samples representing the tumorige-
nesis phase of the viral life cycle. In these three studies, miR-126 was found repressed. is repression will
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Figure 1.28: Regulation of cellular and viral targets by RNA interference during gallid herpesvirus type 2
(GaHV-2) infection. −− > Increased miR expression. –— Repression of expression.
be characterized in the context of this PhD program and the role of this cellular miRNA during GaHV-
2-induced lymphomagenesis will be addressed. e miRNAs gga-miR-21 and gga-miR-221/miR-222 are
expressed at high levels during GaHV-2 latency and tumorigenesis (Lambeth et al., 2009; Stik et al., 2013).
ese miRNAs inhibit expression of a regulator of the cell cycle, p27Kip1 (Lambeth et al., 2009), a cyclin
dependent kinase inhibitor which controls the transition from G0 to G1 phases of the cell cycle; inhibition
of P27Kip1 promotes cell proliferation and growth (gure 1.28). Inhibition of PDCD4 by gga-miR-21 may
promote survival and proliferation of GaHV-2 infected cells (Stik et al., 2013).
e miRNAs gga-miR-130a, gga-miR-103-3p, gga-miR-181a, gga-miR-26a and miR-126 are repressed dur-
ing GaHV-2 tumorigenesis (Han et al., 2016a,b; Lian et al., 2015; Li et al., 2014b; Stik et al., 2013). All these
miRNAs have a potential role as tumor suppressor with an impact on cell proliferation and migration. e
repression of gga-miR-130a allows the expression of the protein homeobox A3 (HOXA3) and MyoD fam-
ily inhibitor domain containing (MDFIC) implicated in cell proliferation and migration (Han et al., 2016b).
HOXA3 is a DNA binding transcription factor which is part of a cluster of homeobox genes. is tran-
scription factor was shown to regulate gene expression, morphogenesis, dierentiation, cell proliferation
and migration (Chisaka and Kameda, 2005; Mace et al., 2005). MDFIC is a member of the MyoD family
protein characterized by a specic cysteine-rich C-terminal domain. It participates to cellular processes
by modulating the Wnt and c-jun N-terminal kinase pathways (Kusano and Raab-traub, 2002). Gga-miR-
103-3p was shown to target cyclin E1 (CCNE1) and the transcription factor E2F dimerization partner 2
(DP-2) (TFDP2). ese proteins are implicated in cell cycle by allowing transition G1/S phase during the
cell cycle (Ekholm and Reed, 2000; Mazumder et al., 2004) and activation of cell cycle regulated genes,
respectively. Despite the fact that these two proteins are implicated in cell cycle regulation, repression
of gga-miR-103-3p promotes cell migration (Han et al., 2016a). e two last miRNAs, gga-miR-181a and
gga-miR-26a, were shown to be implicated in cell proliferation by targeting MYBL1 and NIMA related
kinase 6 (NEK6), respectively (Lian et al., 2015; Li et al., 2014b). MYBL1 is part of the Myb proto-oncogene
family and is a transcription factor which transactivates promoter by recognition of a specic sequence
(YAACG/TG). It has a role in cell proliferation, in B cell dierentiation and cell lymphoma transformation
(Lian et al., 2015). NEK6 is a mitotic kinase belonging to the NEK family. It contributes at establishing the
microtubule-based mitotic spindle and controls cell proliferation and survival (Li et al., 2014b).
In human, other herpesviruses from gammaherpesvirus subfamily (HHV-4 and HHV-8), able to induce
tumorigenesis, were shown to also modulate miRNA expression during infection (Fiorucci et al., 2015).
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Table 1.5: Cellular microRNAs found over- or under-expressed during GaHV-2-induced tumorigenesis
Stik et al,2013 Tian et al,2012 Yao et al,2009
Cellular miRNAs repressed
miR-126 0.4 1.8 0.5
miR-26a 0 1.4 1
miR-155 0 ND 0.3
miR-181a 0.5 0.5 ND
miR-223 0.25 1.6 0.2
Cellular miRNAs overexpressed
miR-146a ND 0.4 ND
miR-146b 0 ND 3
miR-146c 5 ND ND
miR-21 2 0.6 ND
miR-221 3.5 1.7 4
Table notes: ND stands for not determined. Numbers represent the factor of overexpression or
repression evaluated in the three dierent studies.
As mentioned previously, HHV-4 triggers the formation of dierent cancers. In EBV-positive Burki’s
lymphoma miR-28 is repressed contributing to lymphomagenesis (Fiorucci et al., 2015). In NPC, miR-204
was shown repressed while miR-155 was shown overexpressed. e repression of miR-204 is associated
to the most aggressive and poor prognostic phenotype of NPC (Ma et al., 2014). Moreover, this miRNA
was found to directly target cell division cycle 42 (cdc42) contributing to the inhibition of cell invasion
and metastasis (Ma et al., 2014). e overexpression of miR-155 stimulates the ability of NPC to control
cell proliferation, cell migration and invasion (Zhu et al., 2014).
On the other hand, HHV-8 induces several cancers. Lile is known about the impact of cellular microR-
NAs on these cancers. Several miRNAs were observed to be repressed (miR-125b-1-3p and miR-1183)
while others were observed to be overexpressed (miR-126-3p, miR-199a-3p and miR-16-5p) in Kaposi’s
sarcoma samples compare to adjacent healthy tissues (Wu et al., 2014). e deregulation of these miRNAs
could have a crucial role in the progression of Kaposi’s sarcoma.
e analysis of functional mRNA target of miRNAs helps to understand mechanisms implicated in virus
infection, replication and tumorigenesis. e modulation of viral and cellular miRNA expression helps
the virus to escape from immune system, maintain latency, transformation of latently infected cells and
propagated tumoral cells into organisms.
1.5.6 Post-translational modications
Lile is known about post-translational modications during GaHV-2 infection. e capsid precursor
(pro-capsid) is composed of four proteins surrounding an internal scaold (Laurent et al., 2007). is scaf-
fold is composed of two proteins, UL26 and UL26A, which are processed from a common precursor with
protease activity at two cleavage sites. e precursor rst undergoes autocleavage at the R site, releasing
the N-terminal protease domain, which cleaves at the M site, releasing a 25 amino acid segment promoting
the aachment of the scaold to the capsid.
e glycoprotein gB represents the major component of the GaHV-2 viral envelope and is composed of
three glycoproteins (Yoshida et al., 1994); gp100 is formed by the homodimer pr44/pr44 (pr88) and is gly-
cosylated (gure 1.29 A, B) , while gp60 and gp49 are formed aer cleavage of gp100 (gure 1.29 C) and
may play a role in immune evasion (Sithole et al., 1988). Glycoprotein C (gC) is the major antigenic protein
of GaHV-2 (Isfort et al., 1986); it is secreted from infected cells and may play a role in immune evasion.
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A 47 kDa precursor protein, pr47, is cleaved to another precursor, pr44 (44 kDa), which undergoes N-
glycosylation, leading to the formation of two mature proteins, gp57 (57 kDa) and gp61 (61 kDa), diering
in the addition of a sugar residue (gure 1.29 D, E) (Isfort et al., 1986). ese post-translational modica-
tions support correct scaolding of the capsid and may inuence the immune response to GaHV-2.
1.5.7 Conclusion
Cancers are characterized by six hallmarks (gure 1.30); during GaHV-2 infection, numerous viral proteins
and transcripts contribute to lymphomagenesis by acting on at least four of these hallmarks. Regulation
of viral and cellular gene expression during GaHV-2 infection is a complex process that is not fully un-
derstood; several major questions remain unanswered: (1) what are the factors controlling the switch
from latency to the lytic phase; (2) what is the contribution of latency to transformation; and (3) what are
the stimuli for and events involved in reactivation? Further studies are necessary to investigate all these
processes.
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Figure 1.29: Maturation of gallid herpesvirus type 2 (GaHV-2) glycoproteins. (I) GaHV-2 glycoprotein B com-
plex contains two functional glycoproteins (gp60 and gp49). ese are formed from the precursor pr44, which
homodimerizes into another precursor, pr88 (A). is precursor undergoes N-linked glycosylation (B) to give the
glycoprotein gp100, which is cleaved into the two mature glycoproteins gp60 and gp49 (C). (II) GaHV-2 glycopro-
tein C can have molecular weights of 57 and 61 kDa (gp57 and gp61, respectively), which can be explained by the
addition or removal of a sugar group on this glycoprotein. e maturation begins with the cleavage of the precursor
pr47, pr44 (D), which is then N-linked-glycosylated to produce gp57 and gp61 (E) (Isfort et al., 1986).
Figure 1.30: e six hallmarks of cancer and mechanisms used by gallid herpesvirus-2 (GaHV-2) to induce
cancer. + for positive transcriptional regulation. Repression of gene expression. B cell lymphoma 2 (Bcl-2) is an
anti-apoptotic protein. Programmed cell death protein 4 (PDCD4), mothers against decapentaplegic homologue 2
(SMDA2) and Bcl-2l13, a member of the Bcl2 family, are pro-apoptotic proteins. Matrix metalloprotease-3 (MMP-3)
is implicated in the degradation of the extracellular matrix. vTR is the viral RNA telomerase subunit. P27KIP1 is a
cyclin dependent kinase (CDK) inhibitor and controls passage from the G0 to G1 phase.
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1.6 microRNA-126
1.6.1 Host gene
In human cells, the host gene of miR-126 is the epidermal growth factor like-7 (eg-7 ). is gene possesses
10 exons and the pre-miRNA-126 is localized in the seventh intron into a cpG island (Saito et al., 2009).
EGFL-7 was shown to be mainly expressed in endothelial cells (Nikoli et al., 2013; Nikolic et al., 2010;
Schmidt et al., 2007). It was also observed to be expressed in primordial germ cells (Campagnolo et al.,
2008) and neurons (Nikolic et al., 2010) indicating that EGFL-7 has several biological functions and not
only in vascular system.
At transcriptional level, it was found that eg-7 possesses three alternative isoforms transcribed from
three separate promoters (gure 1.31) (Saito et al., 2009). A long, a short and an alternative transcripts.
e long transcript covers the eg-7 full length coding region, the short transcript begins in the seventh
exon (just upstream the pre-miR-126 location) and the alternative transcript begins from an alternative
exon localized in the CpG island of intron 2 and cover the coding region of the gene (Saito et al., 2009).
EGFL-7 protein is secreted in the extracellular matrix (ECM) at the surface of endothelial cells via the in-
teraction with a component of the ECM named α V β 3 integrin (Nikoli et al., 2013). is protein possesses
ve dierent domains (Nikolic et al., 2010). From N-terminal to C-terminal, the rst domain consists on a
signal peptide, followed by an emilin like domain (EMI). is domain is a cysteine rich repetitive element
oen detected in ECM proteins. Close to EMI domain, two EGF-like domains are present giving the name
of the protein. e last element is the coiled coil domain binding Ca2+ (Nikolic et al., 2010).
Box1: denition
Vasculogenesis: refers to the dierentiation of endothelial precursor cells, or an-
gioblasts, into endothelial cells and the de novo formation of a primitive vascular
network.
Angiogenesis: refers to the growth of new capillaries from preexisting blood ves-
sels either via sprouting or intussusception (new blood vessel is created by spliing
of an existing blood vessel in two).
EGFL-7 is implicated mainly in the vasculogenesis and to a less extent to the angiogenesis process (de-
nition of vasculogenesis and angiogenesis in box 1) (Nikolic et al., 2010; Kuhnert et al., 2008). A deletion
of EGFL-7 in a model of zebrash embryo led to the incapacity of endothelial cells to form a tube with a
lumen (Parker et al., 2004; Strilic et al., 2009). During vasculogenesis, EGFL-7 is assumed to create an envi-
ronment which facilitates the local motility of endothelial cells during tube formation. Nevertheless, this
hypothesis is controversial. A study showed a positive impact of EGFL-7 on endothelial cells migration
in mouse (Campagnolo et al., 2005), while others did not observe migration of endothelial cells (HUVEC)
Figure 1.31: Human epidermal growth factor like-7 (egfl-7) alternative transcript. Black bars represent in-
tron. Grey boxes represent exons. e white box represents an alternative exon. S1, S2 and S3 are the three alterna-
tive transcriptional start sites of the human eg-7 gene. e ATG represents the start codon. (adapted from (Saito
et al., 2009)).
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with EGFL-7 alone or in combination with some ECM proteins (Soncin et al., 2003; Parker et al., 2004;
Schmidt et al., 2007). During angiogenesis, it was found that EGFL-7 supports weak adhesion between
endothelial cells (Parker et al., 2004) and creates an environment where cells aach and detach easily
from each other until they acquire their correct position (Nikolic et al., 2010). In mice, if EGFL-7 is deleted
there is formation of an oversized sprout leading to a loss of endothelial cells migration and nally to a
delayed vascularization in the animal. Finally, EGFL-7 was shown to be a negative regulator of vascular
elastogenesis (Lelie`vre et al., 2008). EGFL-7 inhibits the enzyme lysyl oxidase 2 (LOXL2) implicated in the
deposition of elastin. Hence, EGFL-7 may be implicated in the shaping of the ECM aecting indirectly the
migration of endothelial cells.
EGFL-7 expression is important during the development of the vascular system of the embryo. Hence,
EGFL-7 is overexpressed at the embryonic and neonatal stages. en, EGFL-7 is repressed in mature
blood vessels. EGFL-7 may be expressed again in adult either during a wound requiring the renewal of
blood vessels or during tumorigenesis. However, EGFL-7 is still expressed in highly proliferative tissues
(Schmidt et al., 2007).
1.6.2 Regulation of EGFL-7 and miR-126 expression
Like EGFL-7, miR-126 was shown to be highly expressed in endothelial cells (Harris et al., 2010). MiR-126
expression was characterized in two studies from human model (Saito et al., 2009; Watanabe et al., 2012).
e alternative transcript (with TSS located in a CpG island) of eg-7 was shown to be the main transcript
producing miR-126 (Saito et al., 2009). According to this study, miR-126 expression was not driven by
DNA methylation but by HPTMs in its promoter since a low percentage of methylation was observed in
prostate primary tumor. In another context, Watanabe demonstrated the impact of DNA methylation in
CpG islands on miR-126 expression (Watanabe et al., 2012). When the CpG island in the second intron was
methylated, a decrease of miR-126 was detected while no impact of DNA methylation was observed in the
CpG island surrounding the pre-miR-126. e hypermethylation in the second intron might be implicated
in the inhibition of miR-126 expression from of the alternative transcript (Watanabe et al., 2012). Later,
several studies in dierent human cancers such colorectal cancer, esophageal squamous cell carcinoma
and glioma showed an impact of DNA methylation on miR-126 expression (Zhang et al., 2013; Liu et al.,
2015b; Cui et al., 2016). Despite the result obtained by Saito, DNA methylation is most likely involved in
the regulation of miR-126 expression.
e expression of miR-126 was also shown to be regulated by specic transcription factors (TF). Two re-
sponse elements allowing the binding of enhancers (E26 transformation specic sequence-1 and -2 (Ets-1
and Ets-2)) were identied in human (Harris et al., 2010). Even aer repression of these two TFs, a basal
level of miR-126 expression remains. ese results suggest that either Ets-1 and Ets-2 act in combination
with other proteins or they perform a ne tuning of miR-126 expression. In another study, Krueppel-
like factor 2 (KLF-2) was also identied as a transactivator of miR-126 expression in zebrash (Nicoli
et al., 2010). Monteys and collaborators demonstrated that miR-126 possesses an intronic promoter al-
lowing partially the transcription of the short transcript (Monteys et al., 2010). In order to demonstrate
that this region is a potential promoter, a plasmid containing the pre-miR-126 region alone or with the
potential promoter sequence was transfected into cells that do not express miR-126. e plasmid with
the pre-miR-126 sequence alone showed a low expression while the plasmid with the potential promoter
sequence, presented a signicant increase of miR-126 (Monteys et al., 2010). Recently, the transcription
factor GATA2 was found to regulate positively miR-126 expression (Hartmann et al., 2016). In silico analy-
sis was performed and putative binding sites of GATA2 were found in the alternative transcript and short
transcript promoters of EGFL-7/miR-126. Nevertheless, GATA2 was found to only have an impact on
miR-126 expression on its alternative transcript promoter and not on the promoter of the short transcript
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just upstream pre-miR-126 sequence (Hartmann et al., 2016).
1.6.3 Functions
MiR-126 in vascular integrity
In a physiological context miR-126 is mainly expressed in endothelial cells (Fish et al., 2008). MiR-126 is
expressed in highly vascularized tissues such as the heart, lungs and kidneys (Qin et al., 2012). As men-
tioned earlier, the main function of miR-126 is to participate in angiogenesis. Nevertheless, miR-126 takes
also part in inammation and carcinogenesis (Harris et al., 2010). Two studies showed the importance of
miR-126 in vascular integrity and angiogenesis (Fish et al., 2008; Wang et al., 2008b). In zebrash, a role
of miR-126 in vascular integrity was found (Fish et al., 2008). ey show that when miR-126 is deleted
it leads to cranial hemorrhage. e blood vessels integrity, the endothelial tube organization were com-
promised. Moreover, collapsed lumen were also observed (Fish et al., 2008). e same conclusions were
obtained by Wang and collaborators in mouse (Wang et al., 2008b). Knockout mice embryo (miR-126-/-)
died during development or perinatally of severe edema, multifocal hemorrhages, blood vessel ruptures.
ese embryos dysplayed a lack of integrity in the blood vessels (Wang et al., 2008b).
Comparison of miR-126/EGFL-7 implication in angiogenesis
As mentioned earlier, EGFL-7 protein also has a function during angiogenesis and mainly during embryol-
ogy. Kuhnert and collaborators found that miR-126 was more important during angiogenesis than EGFL-7
(Kuhnert et al., 2008). is team created two groups of transgenic mice. One group harbored a deletion
of EGFL-7 gene but maintained the expression of miR-126 (EGFL-7-/-) and the other group harbored a
deletion of miR-126 genes without aecting EGFL-7 expression (miR-126-/-). Mice EGFL-7-/- presented
a high rate of viability compared to mice miR126-/-. Deletion of miR-126 led to edema formation due to
a lack a vascular integrity. Since blood vessels are not fully mature, hemorrhages were observed in sub-
cutaneous region and in the jugular vein of the embryo. In 50 % of cases, miR-126 deletion leads to death
of the embryo while mice EGFL-7-/- presented almost a normal phenotype. Altogether these data indicate
a more important role of miR-126 in angiogenesis in comparison to EGFL-7 in embryonic stages (Kuhnert
et al., 2008).
MiR-126 targets
Targets in the context of angiogenesis e functions of miR-126 can be explained by the study of its
targets. During angiogenesis, miR-126 is a regulator of the vascular endothelial growth factor (VEGF)
induced-signaling pathway. When a tissue does not need formation of new blood vessels, the VEGF
induced-signaling pathway is inhibited by sprouty-related protein with EHV-1 domain 1 (SPRED1) and
the phosphatidylinositide 3-kinase regulatory subunit 2 (PI3KR2) also named p85β (gure 1.32) (Fish et al.,
2008). When angiogenesis is required, miR-126 is expressed and targets SPRED1 and p85β preventing in-
hibition of VEGF signaling pathway (Fish et al., 2008). e repression of the regulatory subunit p85β is
associated with the activation of the catalytic subunit named phosphatidylinositide 3-kinase (PI3K) (Sessa
et al., 2012). e targeting of SPRED1 is also observed in perivascular cells (PVC) also named pericytes
(Pitzler et al., 2016). PVC cover blood vessels and are implicated in their stabilization. When PVC and
endothelial cells are co-cultured, an overexpression of miR-126 was observed leading to the inhibition of
SPRED1 followed by the activation of the Erk1/2 signaling pathway (Fish et al., 2008) (gure 1.32). e up-
regulation of miR-126 was shown to enhance intercellular interactions between PVC and the endothelial
cells (Pitzler et al., 2016). SPRED1 was also validated as a target of miR-126 in cultured primary chicken
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hepatocytes (Wang et al., 2013). In this study, it was shown that SPRED1 was directly targeted by miR-
126. In silico analysis demonstrated that the target site is conserved across species. e chicken predicted
miR-126 binding site sequence is more than 90 % identical to the mouse, human, rat or rabbit. SPRED-1 is
known to regulate the Ras-MAPK signaling in the liver. Some studies on Hepatocellular carcinoma (HCC)
indicated the dysregulation of SPRED1 leading to an inhibition of HCC cells proliferation by decreasing
MAPK activity (Han et al., 2012; Yoshida et al., 2006). Early in angiogenesis process, both VEGF and the
angiopoietin 1 (Ang-1) are required to initiate capillary budding followed by stabilization of the neovessel
for maturation by Ang-1 alone (Sessa et al., 2012). If VEGF is initiated in early embryonic stage alone, it
would lead to an increased permeability of the vessels associated with edema. By targeting p85β, miR-126
allows the PI3K pathways to be initiated by the binding of Ang-1 to its receptor (gure 1.32) (Sessa et al.,
2012).
Targets in the hematopoietic and immune contexts MiR-126 expression is also found in hematopoi-
etic cells with a dierent function. It was demonstrated in zebrash that miR-126 is an important factor
implicated in the development of erythrocytes cells. Hematopoietic stem cells dierentiate through the
inhibition of the factor c-Myb. Two miRNAs are implicated in this inhibition : miR-126 and miR-150. A
ne-tuning of both miRNAs at dierent developmental stages enhance the production of thrombocytes or
erythrocytes. e stem cells will become erythrocytes when miR-126 is more expressed than miR-150. If
the concentration of miR-126 does not increase, stem cells will dierentiate into a megakaryocyte (Grab-
her et al., 2011).
MiR-126 was also found to have a role in the function of T CD4+ cells. T CD4+ cells play a role both
in innate and adaptative immune responses. In the innate immunity, it maintains the balance of anti-
inammatory and proinammatory responses. It was shown that miR-126 deciency promotes the ac-
tivation and the proliferation of T CD4+ in vitro through the targeting of insulin receptor substrate-1
(IRS-1) (Chu et al., 2017). In vivo, in a model of dextan sulphate sodium (DSS)-induced autoimmune col-
itis in mouse, a repression of miR-126 enhances this pathology with a higher number of T CD4+ cells in
splenocytes and an elevated activation phenotype (Chu et al., 2017). IRS-1 is implicated in several path-
ways (Akt, Erk and NF-kappaB pathways) associated with cell proliferation and cell migration triggering
TCD4+ proliferation (gure 1.33).
1.6.4 Tumor suppressor and pro-tumoral roles
MiR-126 was shown to be repressed in numerous human cancers (gastrointestinal cancers, cancers of en-
docrine glands and genital tracts and other cancers such as lung cancer and osteosarcoma) leading to the
conclusion that miR-126 would have a role as tumor suppressor (Ebrahimi et al., 2014). A rst example,
is the repression of miR-126 in lung carcinoma (Crawford et al., 2008). In non-small cell lung cancer and
in lung cancer cell lines, V-crk sarcoma virus CT10 oncogene homolog (Crk) was shown to be directly
targeted by miR-126. Crk is known to have a role in signaling pathways implicated in cell adhesion, pro-
liferation and migration (Feng et al., 2010). An overexpression of miR-126 led to a decrease level of Crk and
to a repression of cell adhesion, migration and invasion (Crawford et al., 2008; Miller et al., 2003). In this
cancer, miR-126 level is correlated with the survival rate of patients. Crk was also shown to be targeted by
miR-126 in gastric carcinoma (Feng et al., 2010). An overexpression of miR-126 in this other cancer type
leads to the same observation than in lung cancers. In both situations, miR-126 overexpression induced a
decrease of cell proliferation by arrest of the cell cycle at G0/G1 stage and a decrease of cell migration and
invasion in vitro and in vivo (Feng et al., 2010). In addition of targeting Crk in gastric cancer, miR-126 was
shown to synergistically target PIK3R2 and polo-like kinase 2 (PLK2), an oncogene and a tumor suppres-
sor genes respectively (Liu et al., 2014). Indeed, the targeting of a tumor suppressor gene by miR-126 in
gastric cancer was also observed in 2011 by Ostubo et al (Otsubo et al., 2011). ese authors showed that
miR-126 was able to inhibit sex determining region Y box 2 (SOX2), giving to miR-126 a role as oncogene.
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Figure 1.32: Schematic representation of signaling pathways regulated by miR-126. Akt and Erk signaling
pathways. Ang1 for Angiopoietin 1. VEGF for vascular endothelial growth factor. VEGFR2 for VEGF receptor 2.
Tie2 receptor for angiopoietin receptor. PIK3R2 for phosphatidylinositide 3-kinase regulatory subunit 2. PI3K for
phosphatidylinositide 3-kinase. PDK-1 for phosphoinositide-depedent kinase-1. Akt also known as protein kinase
B (PKB). RAS, RAF, Mek and Erk are part of the MAPkinase pathway. Erk for extracellular signal-regulated kinases.
SPRED1 for sprouty-related protein with EHV-1 domain.
Figure 1.33: Schematic representation of IRS1 pathway. IGF1 for isulin-like growth factor-1. IR for isulin
receptor. IGF1R for IGF1 receptor. IKKαβ for Iκkinaseαβ. NF-κB for nuclear factor kappa-light-chain-enhancer of
activated B cells. PI3K for phosphatidylinositide 3-kinase. PDK-1 for phosphoinositide-depedent kinase-1. Akt also
known as protein kinase B (PKB). RAS, RAF, Mek and Erk are part of the MAPkinase pathway. Erk for extracellular
signal-regulated kinases. SPRED1 for sprouty-related protein with EHV-1 domain 1.
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Sox2 has a role in growth inhibition via cell cycle arrest and apoptosis. e overexpression of miR-126 in
some cultured and primary gastric cancer cells showed a role of miR-126 in gastric carcinogenesis (Otsubo
et al., 2011).
In B- and T-lineage acute lymphoblastic leukemia (ALL), the expression level of miR-126 varied according
to molecular lesions observed (Fulci et al., 2009). In leukemia with the rearrangement break cluster re-
gion/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL), an overexpression of miR-126 was
observed. While cells having the molecular lesion E2A/PBX1 and mixed-lineage leukemia (MLL/AF4),
showed a repressed expression of miR-126 (Fulci et al., 2009).
In acute myeloid leukemia (AML), miR-126 plays a role in cell survival in vitro (Li2011, article de base).
ey showed in two cell lines derived from acute monocytic leukemia (THP-1) and eosinophilic myelomono-
cytic leukemia (ME-1) an overexpression of miR-126 leading to a decrease of apoptosis. On the other hand,
an inhibition of miR-126 decreases cell survival by increasing apoptosis of cancerous cells. ese data
shows an oncogenic role of miR-126 in AML although its tumor suppressor functions are beer studied
(Li2011).
All these studies suggest that miR-126 has a more complicated behavior than only a tumor suppressor gene
and that miRNA function is not dependent of one target gene but rather from a competition or balance
among these targets genes for a specic type of cancer (Otsubo et al., 2011; Liu et al., 2014).
1.7 Objectives
MicroRNAs (miRNAs) are small single stranded around 21-24 nucleotides long non coding RNAs pro-
cessed from precursor RNAs showing a hairpin structure. MiRNAs are active in very diverse cellular
processes such as dierentiation, proliferation and apoptosis. eir function has been underlined in or-
gan development and in maintaining the proper functioning of dierentiated tissues. Deregulation of the
normal miRNA expression play a critical role in a wide range of human and animal diseases, particularly
in tumors (Pichler and Calin, 2015).
During latency, herpesvirus infection results in the establishment of a dormant state in which a highly
restricted set of viral genes are expressed. is is associated with extensive methylation of CpG motifs
in non-expressed viral genes. Together with these alterations of the viral genome, several host genes un-
dergo epigenetic modications during the latent infection. In some of the human and animal herpesvirus
infections, these epigenetic dysregulations of cellular genes are involved in the development of cancer.
is PhD program was carried out in an animal model of virus induced lymphoma causing the MD in
chicken. is lymphoproliferative disease is the ultimate consequence of chicken infection with virulent
strains of GaHV-2. is Alphaherpesvirinae actually shares several properties with Gammaherpesvirinae
(such as human herpesvirus-4 and -8) which are associated with the development of tumors under specic
conditions in latently infected lymphoid cells. GaHV-2 was shown to modulate the expression of several
cellular miRNAs in chicken. Altered expressions of host-encoded miRNAs were analyzed in vitro and in
vivo samples in several studies (Stik et al., 2013; Tian et al., 2012; Yao et al., 2009). Although only few of
the cellular miRNA deregulations triggered by GaHV-2 were analyzed in depth, these studies suggested
that altered expressions of host miRNAs are involved in the molecular pathways of GaHV-2 oncogenicity.
During this PhD program we focused on a host miRNA, miR-126 since several pieces of evidence suggested
it might be downregulated during GaHV-2 tumorigenesis (Stik et al., 2013; Tian et al., 2012; Yao et al., 2009).
Originally described as a miRNA mediating proper angiogenesis and vascular integrity, miR-126 has been
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reported to impair cancer progression through signaling pathways that control tumor cell proliferation,
migration, invasion and survival. MiR-126 was shown to be downregulated in several human cancers such
as in oral, stomach, colon, lung, breast, cervix, bladder and prostate carcinoma (Ebrahimi et al., 2014). MiR-
126 is an intronic miRNA integrated in the intron 7 of a cellular gene, the epidermal growth factor like
domain 7 (eg-7 ). In human, the laer gene is controlled by three promoters generating three transcripts,
a long, an alternative and a short transcript (Saito et al., 2009). It was shown that epigenetic modications
have an impact on the alternative transcript expression by remodeling the alternative promoter (Saito
et al., 2009; Monteys et al., 2010).
In this context, the core issue of this PhD program is whether miR-126 downregulation is a key event
involved in GaHV-2 oncogenicity. To address this general issue, the following questions will be answered
successively:
• When and to which level is miR-126 actually downexpressed during the course of GaHV-2 infection?
• What are the transcriptional features (initiation of the transcription, splicing isoforms) of the gene
hosting miR-126 in chicken?
• Is miR-126 misexpression related to specic epigenetic paerns in CpG islands of chicken miR-126
host gene?
• Does miR-126 inhibition participate to the cancerous process induced by GaHV-2?
• Is it possible to counteract some of the malignant features of GaHV-2 by restoring miR-126 expres-
sion at dierent steps of the GaHV-2 infection?
A series of experiments will be designed to address these questions and the data obtained will be reported
in three sections. In the rst study, a thorough quantication method of miR-126 expression will be set
up. is tool is essential to compare in the most accurate way miR-126 expression level in any situation
corresponding to the dierent stages of GaHV-2 infection. is method relies on the use of several refer-
ence genes to normalize the expression of the gene of interest allowing to obtain reliable results.
In the second study, we will investigate the miR-126 expression level at the key steps of GaHV-2 infec-
tion (in vitro and in vivo) together with associating this expression level with DNA methylation paern
found in the host gene. e miR-126 expression level will be evaluated by using the reliable quantica-
tion method set up in the rst study. In order to determine whether low miR-126 expression levels are
associated with specic epigenetic signatures and with peculiar transcription proles, DNA methylation
paerns and transcriptional isoforms will be established at miR-126 genomic locus. Another objective
of this study is to test the biological consequences of miR-126 silencing during MD lymphoma develop-
ment. Since miR-126 repression likely plays a pivotal role in altering gene expression paerns during cell
transformation, we will investigate the impact of miR-126 restoration. A strategy will be developed to
overexpress miR-126 and control miRNAs in transformed CD4+ T cells propagated from MD lymphoma.
To this end, we will use a conditional expression system (Tet-on inducible expression plasmids aer se-
lection and integration) that was recently used to modify gene expression in the MDV transformed cells
propagated in vitro (Rasschaert et al., 2016). Aer induction of miRNA expression, cancerous cells will be
characterized in order to assess cell survival and proliferation.
e objective of the third study is to interfere with miR-126 silencing during the natural course of GaHV-
2 infection. To this end, a recombinant GaHV-2 will be produced in order to obtain infectious viruses
that constitutively express the miRNA lost during lymphoma development. e goal of this strategy is to
characterize anti-tumoral potential of miR-126 and to see whether GaHV-2 oncogenic potential might be
impaired when miR-126 expression is maintained along the infection. First steps of this project will be
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carried out in the present PhD program to prepare the material that will be further tested in an in vivo trial.
Recombinant viruses expressing either wild-type or mutated versions of miR-126 will be generated from
a very virulent GaHV-2 strain (RB-1B) cloned as an infectious Bacterial Articial Chromosome (BAC). In-
fectious viruses will be amplied and characterized in vitro to evaluate if the recombinant viruses replicate
to similar levels as the original strain and if this strategy is adapted to overexpress miR-126 together with
viral amplication.
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Since several human viruses are associated with cancer development, animal models are needed to ex-
plore the mechanisms and processes linking viral infection and oncogenesis. is study focuses on gene
regulation and functional roles of a cellular miRNA (miR-126) in an animal model of virus-induced lym-
phoma causing the MD in chickens. During latency, herpesvirus infection results in the establishment of
a dormant state in which a highly restricted set of viral genes are expressed; this is associated with exten-
sive methylation of CpG motifs in non-expressed viral genes. Together with these alterations of the viral
genome, several host genes undergo epigenetic modications during the latent infection. In some of the
human and animal herpesvirus infections, these epigenetic dysregulations of cellular genes are involved
in the development of cancer.
MD is the ultimate consequence of chicken infection with virulent strains of GaHV-2 and is a unique nat-
ural animal model for herpesvirus-induced lymphomagenesis. Several properties of MD lymphoma illus-
trate the relevance of the animal model. (i) MD lymphoma cells overexpress the CD30 antigen, a member
of tumor necrosis factor receptor II family. CD30 overexpression (CD30hi) is a conserved signature found
in neoplastic transformation in human and chicken lymphomas of dierent etiologies (Burgess et al., 2004).
(ii) GaHV-2 expresses a long non coding RNA, the vTR (viral Telomerase RNA), a functional component of
the telomerase complex that promotes MDV induced lymphomagenesis (Kaufer et al., 2011; Chbab et al.,
2010). As a reminder, telomerase reactivation is associated with 85 % of the human malignancies. (iii) e
modulation of gene expression observed in MD induced lymphoma shows the high adaptation level of
the virus to the cell transcriptional network either through the cooperation with cellular TF or through
the expression of viral TF to modulate viral and cellular gene expression. Functional examples of this
crosstalk between cellular and viral transcriptional components were recently reviewed by Gennart and
collaborators (Gennart et al., 2015). (iv) During oncogenesis, GaHV-2 regulates viral and host gene expres-
sion by inhibiting gene translation through a large set of viral miRNAs. In addition, GaHV-2 modulates
the expression of several host miRNAs as described for the upregulated chicken miRNA, miR-21 and the
cluster miR-221/ -222 and for the down-regulated chicken miRNAs miR-26a (Stik et al., 2013; Lambeth
et al., 2009; Li et al., 2014b). In this context of host miRNAs dysregulated during GaHV-2 infection, this
piece of work focused on miR-126 to beer understand the mechanisms that control the expression of this
host miRNA and to address the consequences of its downregulation during MD.
e salient ndings reported in this PhD thesis are :
• e seing up of thorough quantication method permiing the most accurate assessment of miR-
126 expression in dierent biological contexts.
• e demonstration of the repression of miR-126 during the course of GaHV-2 infection and more
precisely during the lymphomagenesis phase.
• e association of miR-126 repression with hypermethylation in CpG islands of chicken miR-126
host gene (eg-7 ).
• A preliminary functional analysis showing that miR-126 inhibition might participate to the cancer-
ous process induced by GaHV-2 with a role in cell proliferation.
• e development of an original strategy to overexpress miR-126 during GaHV-2 infection by gen-
erating a recombinant GaHV-2 possessing a functional miR-126 expression cassee.
Previously, several studies demonstrated the repression of miR-126 in the context of MD (Stik et al., 2013;
Tian et al., 2012; Yao et al., 2009). ese studies limited their quantication analysis in in vitro and in vivo
samples representing the lymphomagenesis phase of GaHV-2. During the PhD program, miR-126 expres-
sion paern was investigated in all the key steps of GaHV-2 infection. Moreover, these quantications
were performed with the use of a thorough quantication method using several reference genes to ensure
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reliable results.
In MD, lile is known about how GaHV-2 modulates and regulates cellular miRNAs during the course of
the disease. e use of epigenetic to deregulated cellular genes, the identication of alternative transcripts
potentially implicated in gene expression regulation and functional analysis results obtained in this study
brought new insights on miR-126 regulation during GaHV-2 induced lymphomagenesis.
Set up of a thorough quantication method
e study of viruses brought detailed understanding of the system biology inherent in virus-host inter-
actions (Bernard N Fields, 2007). Cellular gene expression modulation during viral infection is widely
studied in order to assess how viruses may persist in their hosts, how do they escape from the immune
system and, for some viruses, how do they induce oncogenesis. In order to answer these questions an-
imal experimental models are used. Most of the time, gene quantication is normalized with only one
Reference Gene (RG) without preliminary test leading to misinterpretation of data. In this study it was
demonstrated that according to the RG used data interpretation may lead to dierent conclusions. e use
of several RGs for gene normalization is then crucial to obtain reliable results with a biological meaning
especially if subtle changes in gene expression are expected.
To properly assess miR-126 expression levels, quantitative reverse-transcription PCR (qRT-PCR) was de-
velopped. is technique is evidencing advantages over other methods such as sensitivity, dynamic range
and capacity for multiplexing (Hugge et al., 2005). However, the data analysis from qRT-PCR is challeng-
ing. e accuracy of the results is largely dependent on proper data normalization. As numerous variables
inherent to a qRT-PCR experiment need to be controlled in order to dierenciate experimentally induced
variations from true biological changes. To limit these technical variations, several internal controls must
be used as reference genes (RGs). In this study, six dierent usually used RGs (gapdh, β-actin, sdha, 18Sr-
RNA, hmbs and U6) were assessed in the dierent samples to normalize miR-126. ese candidates belong
to dierent functional classes, reducing the possibility of confounding co-regulation. Nevertheless, in lit-
erature, it is recommended to use other small non-coding RNAs for normalization of a microRNA since
their biogenesis is similar (Mestdagh et al., 2009; Cassol et al., 2016; Li et al., 2014a). ese include both
small non-coding RNA such as U6 that is extensively used and small nucleolar RNAs. In human, several
miRNAs were considered to be stably expressed (let-7a, miR-26a, miR-191 and miR-103) and widely used
for normalization in tumor samples (Chang et al., 2010). e selection of appropriate reference genes
to normalize miRNA expression was performed also in other models such as bovine and plant (Li et al.,
2014b; Cassol et al., 2016). Six non-coding RNA expression were assessed in dierent bovine solid tissues
(lung, muscle, fat, heart, kidney, spleen, uterus and small intestine) (Li et al., 2014b). In all these tissues,
U6, miR-191 and let-7f were demonstrated to be the most stably expressed. As well as for coding-protein
genes used for normalization or mRNA, preliminary experimental assay needs to be performed to select
the most stably expressed miRNAs in the dierent samples representative of the experimental conditions
used. It is important to note that miRNAs pose a signicant challenge for normalization, since they rep-
resent as lile as 0.01 % of the total mass of RNA in sample, and this percentage can vary signicantly
across dierent samples (Liang et al., 2007). Moreover, they are tightly regulated RNAs in numerous bio-
logical processes making dicult to nd stably expressed miRNAs in the dierent experimental conditions
studied. Non-coding RNAs were not systematically used as reference genes for miRNAs. A recent paper
quantied miR-159 in leaves, roots and stem in cucumber aer infection with the cucumber green mole
mosaic virus (CGMMV) and the authors normalized the miRNA with two protein-coding genes (Liang
et al., 2018).
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Repression of miR-126 expression during GaHV-2 induced lymphomagenesis
In the context of MD, studies were more dedicated to viral miRNAs characterization rather than host miR-
NAs (Burnside et al., 2006, 2008; Yao et al., 2009; Muylkens et al., 2010; Stik et al., 2014; Parnas et al., 2014;
Xu et al., 2011; Yao and Nair, 2014). Expression and functional roles of these viral miRNAs were assessed
all along GaHV-2 viral life cycle (Muylkens et al., 2010; Parnas et al., 2014; Xu et al., 2011; Yao and Nair,
2014). Several viral miRNAs were demonstrated to play important roles in tumor development with an
implication in apoptosis, cell survival and immune escape.
Several studies suggested that mis-expression of host miRNAs is one of the corner stones in the her-
pesvirus induced oncogenesis (Fiorucci et al., 2015; Catrina et al., 2014; Lian et al., 2012). is work focuses
on host-pathogen relation in the context of MD by studying a host miRNA (miR-126) repressed during
GaHV-2 induced lymphomagenesis. Previous studies assessed host miRNAs expression paern with high
throughput sequencing methods (Lian et al., 2012; Tian et al., 2012; Stik et al., 2013; Yao et al., 2009). Some
host miRNAs were found upregulated while other were found downregulated. Functional analysis were
performed for only few of them (Stik et al., 2013; Han et al., 2016a,b; Lian et al., 2015). Nevertheless, this
brought insights on host miRNAs implication during GaHV-2 induced lymphomagenesis with roles in cell
survival, cell proliferation and migration. Since miR-126 was shown to be repressed during oncogenesis,
we decided to assess if its inhibition participates to the cancerous process induced by GaHV-2. A strategy
was developed to overexpress miR-126 and control miRNAs in transformed CD4+ T cell propagated from
MD lymphoma. Preliminary experiment performed in the context of this PhD program showed a potential
impact of miR-126 on cell proliferation. Other functional analysis are needed to have a comprehensive
overview on how repression of miR-126 is implicated in tumor formation. Another strategy that may be
used to address this question is the silencing of miR-126 expression in a cellular context where it is highly
expressed.
Studies about host miRNAs during GaHV-2 infection are a thematic in expansion. While the focus was
on viral genes, a few years ago other factors have been taken into account to understand this complex
host-pathogen relation. e expression paern of cellular mRNAs were assessed from samples of in-
fected chickens (Dang et al., 2017; Chen et al., 2011; Haq et al., 2010). Dierent signaling pathways were
shown to be modulated all along GaHV-2 infection such as the JAK/STAT signaling pathway implicated
in cell dierenciation, proliferation, development, apoptosis and inammation (Dang et al., 2017). A study
demonstrated that GaHV-2 transformed cells obtained from the liver present a dierent metabolism com-
pared to uninfected cells (Chen et al., 2011).
Another factor that might be implicated in miR-126 repression is the major viral oncoprotein Meq. is
protein possesses a bZIP domain allowing formation of homodimers or to dimerize with other cellular and
viral proteins possessing a bZIP domain, such as c-Jun (Levy et al., 2003). is heterodimer targets the Meq
responsive element I (MERE I) found in the cellular miR-21 promoter (Stik et al., 2013). is heterodimer is
known as transactivating gene expression. e assumption is that the heterodimer might bind on miR-126
promoter and might induce its expression when DNA is not methylated. In the opposite case, no binding
would be possible in the presence of a high level of methylation, preventing miR-126 expression during
GaHV-2 induced tumorigenesis. Nevertheless, this assumption is unlikely since no MERE I was found
within miR-126 host gene.
Another assumption would be the implication of two cellular transcription factors, c-Myc and myc asso-
ciated factor X (MAX), in miR-126 expression regulation. C-Myc and MAX are able to form a heterodimer
and are known to transactivate gene expression. C-Myc has been linked to immune dysfunction, can-
cer development and neoplastic transformation (Trop-Steinberg and Azar, 2018). In silico analysis was
performed on miR-126 host gene and responsive elements (RE) for these two transcription factors were
detected in the most discriminative region of the CpG island. Shis in the DNA methylation paerns
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detected in RE corresponding to these transcription factors might trigger dierential binding of these
transcription factors.
Downregulation of miRNA-126 and epigenetic regulation
In most tumors, global DNA methylation is low with local spots of high DNA methylation at particular
gene promoters (Timp and Feinberg, 2013). is phenomenon is thought to be an adaptative advantage
for the cancer cells due to silencing of tumor suppressor genes. In vivo miR-126 expression level was
shown to be nearly extinguished in tumor CD4+ T cells infected with GaHV-2. Characterization of this
repression revealed a hypermethylation within miR-126 host gene (eg-7 ) at the CpG island 2 (CpG2)
when comparing samples from infected to uninfected birds in vivo. e study of DNA methylation was
focused on CpG2 since it was found in human to be implicated in miR-126 gene regulation (Saito et al.,
2009). DNA methylation and histone post-translational modications (HPTMs) were demonstrated to be
implicated in miR-126 expression in prostate cancer cell lines (Saito et al., 2009). Several other studies
in human cancers brought the importance of DNA methylation to induce miR-126 repression (Liu et al.,
2015b; Cui et al., 2016; Saito et al., 2009; Watanabe et al., 2012). In human esophageal squamous cell carci-
noma (ESCC) the repression of miR-126 is associated with the overexpression of DNA methyltransferase
1 (DNMT1). antication of the dierent DNMTs (de novo (DNMT3A and 3B) and maintance (DNMT1)
enzymes) would be interesting to understand the upstream pathway involved in the hypermethylation.
Epigenetic modulations are evidenced in the context of cancer disease. During this work, the focus was
restricted to one CpG island giving an incomplete view on how miR-126 gene expression is regulated. e
role of DNA methylation in CpG island is part of the cancer epigenetics signature but the existence of
CpG island shores (CGI shores) and nucleosome positioning were unknown until recently.
In colon cancer, most discriminative dierences in methylation paerns between tissues occur outside
CpG islands in sequences up to 2 Kb distant called CpG island shores (CGI shores) (Irizarry et al., 2009).
ese regions are implicated in physiological processes such as cell dierenciation and reprogramming
but also in disease such as cancer (Doi et al., 2009). Two potential roles of CGI shores are proposed: (i)
they are sites of alternative transcription and enhancer regions. Hypomethylation of the CGI shores acti-
vates alternative TSS. (ii) CGI shores are boundaries surrounding CpG islands protecting them from DNA
methylation. Erosion of these sharply dened boundaries results in altered gene expression. Cancers
ignore the demarcated boundary between high and low methylation that is dened by CGIs (Timp and
Feinberg, 2013). If boundaries between high and low methylation shis outwards, the CGI shores become
hypomethylated. Conversely, if boundaries between high and low methylation shis inwards, toward
CpG islands, CGI shores is found hypermethylated.
Another level of epigenetic regulation is the chromatin organization in euchromatin and heterochromatin
that is controlled by nucleosome positioning and post-translational modications of histone tails (Wang
et al., 2007). Transcriptional activity is possible when there is nucleosome depletion (Kaplan et al., 2009),
positive histone marks and the presence of histone variants such as H3.3 and H2A.Z (Zofall et al., 2009).
In addition, bivalents regions exist with a combination of an active mark (H3K4me3) and a negative mark
(H3K27me3). ese regions are associated to hypermethylated CpG islands in cancer (Ohm et al., 2007).
In this study, we focused on small epigenetic structure (CpG island). New high-throughput techniques
brought the existence of large epigenetic structures (Timp and Feinberg, 2013). e genome is partionated
into large euchromatin and heterochromatin domains named large organized chromatin lysine modica-
tion (LOCKs) and lamina associated domains (LADs). ese two domains increase in size during devel-
opment and 80 % of them overlap (Timp and Feinberg, 2013; Hu et al., 2012; Peric-hupkes et al., 2010).
(i) LOCKs are domains enriched with heterochromatin post-translational modication such as H3K9me2.
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ese domains expand during dierentiation while a loss is observed in cancer (Wen et al., 2009). During
oncogenesis process, epithelial-mesenchymal transition (EMT) occurs altering LOCKs domain composi-
tion (Timp and Feinberg, 2013). e chromatin is reprogrammed with a decrease of histone negative mark
(H3K9me2) and an increase in histone positive marks (H3K4me3 and H3K36me3). (ii) LADs are DNA se-
quences associated with proteins from nuclear lamina (Zullo et al., 2008). Gene repression is associated
with these regions. ese two dierent large epigenetic structures allow to obtain large-scale epigenetic
alteration in cancer.
All of these pieces of information about epigenetics underlines the fact that our study is very limited and
would need a more global approach. DNA methylation should be studied in association with HPTMs.
Two studies demonstrated that transcriptional gene silencing seems to be driven by histone modications
before DNA methylation changes (Bachman et al., 2003). It would be interesting to assess histone marks
on the CpG island studied as well as a larger locus to identify potential implication of CpG shores on
miR-126 expression.
Another point to discuss in this study is the very high percentage of DNA methylation observed in T
CD4+ transformed cell lines propagated in vitro (86 %), especially when the situation is compared with
in vivo samples (from 7 to 22 %). is statement was also made in a previous studies where marked hy-
permethylation of CGIs was observed in stable cell lines (mouse embryo cells) and immortalized cell lines
(immortal broblast cell lines) (Timp and Feinberg, 2013). e paern of DNA methylation in immortal-
ized cell lines does not represent what is found during an in vivo challenge. Cell lines are therefore not
the most appropriate sample to learn about epigenetic regulation. e immortalization process seems to
modulate epigenetic machinery leading to aberrant DNA methylation paern in the cells.
As mentioned in the introduction, several evidences indicated that miRNAs have nuclear functions. It
was shown that mature miRNAs may shule from the cytoplasm to the nucleus (Catalanoo et al., 2016).
Besides their cytoplasmic function as translation repressor, miRNA may associate with RISC components
in the nucleus to regulate transcription. Even if only few examples have been studied in depth, strong
evidences support that miRNAs contribute either to transcriptionnal repression (Zardo et al., 2012) or
transcriptional activation (Place et al., 2008; Turner et al., 2014). Dierent mechanisms were described but
altogether these studies indicated that miRNAs are able to recruit on specic DNA locus the chromatin re-
modelling machinery and the components of the DNA CpG methylation (Zardo et al., 2012). us miRNA
may be considered as original triggers of epigenetic modications that together result in transcriptional
gene silencing (TGS) or transcriptional gene activation (TGA). It would be interesting to assess if repres-
sion of miR-126 is linked to miRNAs-induced silencing. e binding on a specic locus of miR-126 host
gene might trigger epigenetic modication resulting in miR-126 repression during tumorigenesis.
Perspectives
In order to test the biological eects induced by miR-126 silencing during MD lymphoma development, a
strategy was developed in order to restore miR-126 expression in transformed CD4+ T cells propagated
from MD lymphoma. We used a conditional expression system (Tet-on inducible expression plasmids aer
selection and integration). Aer induction of miRNA expression, cancerous cells were characterized in
order to assess cell survival and proliferation. e preliminary functional analysis showed that miR-126
inhibition might participate to the cancerous process induced by GaHV-2 with a role in cell proliferation.
In order to complete the functional analysis, other phenotypes should be investigated such as the role
of miR-126 in apoptosis, the inuence of miR-126 in cell proliferation measured through colony forma-
tion assay aer a long term miR-126 overexpression. Moreover, it would be interesting to characterize
mechanistic consequences of miR-126 restoration by analyzing the expression level of several candidate
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targets through high throughput RNA seq and proteomic approaches. A rst analysis would be to deci-
pher miR-126 interaction with two candidate target genes, namely CrK (Chicken Tumor Virus number 10
regulator of kinase), a previously characterized miR-126 target and TRPC6 (Transient recetpro potential
canonical 6). Crk is known to have a role in signaling pathways implicated in cell adhesion, proliferation
and migration (Feng et al., 2010). Recent data suggest that TRPC6-mediated elevation of intracellular Ca2+
stimulates cell proliferation and that inhibition of TRPC6 aenuates cell proliferation and invasion.
To complement the in vitro functional analysis, a part of this work concentrated on the creation of a re-
combinant GaHV-2 that constitutively expresses the miRNA lost during lymphoma development. e
aim is to interfere with miR-126 silencing during the natural course of GaHV-2 infection. It is an original
system to clearly dene the role of miR-126 in MD progression.
An interesting perspective would be to create recombinant viruses with other cellular pre-miRNAs (sep-
arately or in cluster) already known repressed during the Marek’s Disease such as miR-223 and miR-26a
(Tian et al., 2012; Li et al., 2014b). miR-223 has a physiological role in the fate of myeloid precursor. Its
deregulation was shown to be implicated in tumorigenesis in human (Li et al., 2011; Taı¨bi et al., 2014).
miR-26a plays signicant roles in growth, development and cell dierentiation of dierent tissues (Gao
and Liu, 2011). is miRNA was found downregulated in several human cancers such as bladder cancer,
breast cancer and rhabdomyosarcoma (Maillot et al., 2009; Ciarapica et al., 2009).
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• Review paper as rst author:
1) Gennart I., Coupeau D., Pejakovic S., Laurent S., Rasschaert D., Muylkens B. (2015).
Marek’s disease: genetic regulation of gallid herpesvirus 2 infection and latency. The Vet-
erinary Journal, 205:339-348.
• Original paper as rst author : submied to PloS ONE (in revision):
2) Gennart I., Regnier M., Rauw F., Wiggers L., Coupeau D., Lambrecht B., Muylkens B. In-
uence of anesthesia on gene expression analysis in experimental model of virus-induced
lymphoma. PloS ONE (in revision)
• Original papers as second author:
In collaboration with the University of Tours, DNA methylation paerns were established for ICP4
and ICP27 promoters, controlling the expression of these two Immediate Early genes of GaHV-2.
is work was done during the second year of the PhD program in collaboration with the TLVI
(Transcription Lymphome Viro-Induit) research group. ese results were included in two original
papers that are published in the “Journal of General Virology”.
3) Strassheim S., Gennart I., Muylkens B., AndreM., Rasschaert D., Laurent S. (2016). Onco-
genic Marek’s disease herpesvirus encodes an isoform of the conserved regulatory imme-
diate early protein ICP27 generated by alternative promoter usage. Journal of General
Virology, 97:2399-2410.
Herpesvirus gene expression is temporally regulated, with immediate early (IE), early (E) and late
(L) genes. ICP27, which is involved in post-transcriptional regulation, is the only IE gene product
conserved in all herpesviruses. We show here that the ICP27 transcript of the oncogenic Marek’s dis-
ease virus shares the same polyadenylation signal as the bicistronic glycoprotein K–ICP27 transcript
and is regulated by alternative promoter usage, with transcription from its own promoter (pICP27)
or that of gK (pgK). e pgK can generate a spliced ICP27 transcript yielding an N-terminal-deleted
ICP27 isoform (ICP27DN) that, like ICP27, co-localizes with the SR protein in infected cells, but with
a diuse nuclear distribution. e pICP27 includes functional responsive elements (REs) for SP1,
AP1 and CREB, is essentially active during the lytic phase and leads to exclusive expression of the
native form of ICP27. e alternative promoter, pgK, including active REs for GATA, P53 and CREB,
preferentially generates the gK transcript during the lytic phase and the spliced ICP27 transcript
(ICP27DN) during the latent phase. An analysis of the DNA methylation marks of each promoter
showed that pgK was systematically demethylated, whereas pICP27 was methylated during latency
and demethylated during the lytic stage. us, MDV ICP27 gene expression is dependent on alter-
native promoters, the usage of which is regulated by DNA methylation, which diers between viral
stages.
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4) Rasschaert P., Gennart I., Boumart I., Dambrine G., Muylkens B., Rasschaert D., Laurent
S. (2018). Specic transcriptional and post-transcriptional regulation of the major imme-
diate early ICP4 gene of GaHV-2 during the lytic, latent and reactivation phases. Journal
of General Virology, 1-14.
Transcriptional and post-transcriptional mechanisms are involved in the switch between the lytic,
latent and reactivation phases of the viral cycle in herpesviruses. During the productive phases,
herpesvirus gene expression is characterized by a temporally regulated cascade of immediate early
(IE), early (E) and late (L) genes. In alphaherpesviruses, the major product of the IE ICP4 gene is a
transcriptional regulator that initiates the cascade of gene expression that is essential for viral repli-
cation. In this study, we redene the infected cell protein 4 (ICP4) gene of the oncogenic Marek’s
disease virus (MDV or gallid herpesvirus 2) as a 9438 nt gene ended with four alternative poly(A)
signals and controlled by two alternative promoters containing essentially ubiquitous functional
response elements (GC, TATA and CCAAT boxes). e distal promoter is associated with ICP4 gene
expression during the lytic and the latent phases, whereas the proximal promoter is associated with
the expression of this gene during the reactivation phase. Both promoters are regulated by DNA
methylation during the viral cycle and are hypermethylated during latency. Transcript analyses
showed ICP4 to consist of three exons and two introns, the alternative splicing of which is associ-
ated with ve predicted nested ICP4ORFs. We show that the ICP4 gene is highly and specically
regulated by transcriptional and post-transcriptional mechanisms during the three phases of the
GaHV-2 viral cycle, with a clear dierence in expression between the lytic phase and reactivation
from latency in our model.
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